Uncovering novel pathway of liver disease: TonEBP promotes development, recurrence, and chemotherapy resistance of hepatocellular carcinoma via inflammation and cancer stem cells by Lee, Jun Ho
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 





Uncovering novel pathway of liver disease: TonEBP 
promotes development, recurrence, and 
chemotherapy resistance of hepatocellular carcinoma 









Jun Ho Lee 
 









Uncovering novel pathway of liver disease: TonEBP 
promotes development, recurrence, and 
chemotherapy resistance of hepatocellular carcinoma 

















Department of Biological Sciences 
 
 
Graduate School of UNIST 
 
Uncovering novel pathway of liver disease: TonEBP 
promotes development, recurrence, and 
chemotherapy resistance of hepatocellular carcinoma 










submitted to the Graduate School of UNIST 
in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
 






11. 20. 2018 
Approved by  
  
Advisor 
Hyug Moo Kwon 
Uncovering novel pathway of liver disease: TonEBP 
promotes development, recurrence, and 
chemotherapy resistance of hepatocellular carcinoma 
via inflammation and cancer stem cells 
 
 
Jun Ho Lee 
 
 
This certifies that the thesis/dissertation of Jun Ho Lee is  
approved. 






Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. In 
addition to diverse etiological agents and wide heterogeneity in individual tumors, inherent resistance 
to chemotherapeutic agents and a very high rate of recurrence are the major contributing factors. 
These pathological properties stem from inflammation and liver cancer stem cells (CSCs), but the 
underlying mechanisms are not completely understood. Tonicity-responsive enhancer binding protein 
(TonEBP), also known as NFAT5, is a central component of the pro-inflammatory enhanceosome 
leading to the pathogenesis of a variety of chronic inflammatory diseases. Although inflammation is 
intimately associated with the pathogenesis of HCC, the role of TonEBP is unknown. We aimed to 
identify a function of TonEBP in HCC. 
Here we show that TonEBP in tumors is overexpressed compared to adjacent non-tumor tissues in 
92.6% of patients with HCC regardless of etiology in association with suppression of miR-223. 
Notably, the expression of TonEBP in tumors and adjacent non-tumor tissues is associated with poor 
prognosis of patients. TonEBP is required for inflammation-mediated initiation and growth of HCC. 
In mouse models of HCC, three common sites of TonEBP action in response to diverse etiological 
agents leading to tumorigenesis and tumor growth were found: cell injury and inflammation, 
induction by oxidative stress and stimulation of the cyclooxygenase-2 (COX-2) promoter. TonEBP 
drives the expression of COX-2 in association with YY1 and p300. Although TonEBP-dependent 
stimulation of COX-2 was dispensable for poor prognosis in patients, the expression of TonEBP in 
tumors and adjacent non-tumor tissues predicts recurrence, metastasis and death of patients. 
Functional relevance of TonEBP in poor prognosis is driven by CSCs. TonEBP promotes self-renewal, 
maintenance, and tumorigenic activity of liver CSCs. Chemoresistance of CSCs was mediated by 
TonEBP in combination with higher repair activity. We found that TonEBP-mediated DNA repair was 
carried out by ERCC1/XPF dimer. The TonEBP-ERCC1/XPF complex activated ATM in response to 
DNA damage leading to activation of transcription factors and expression of pro-inflammatory 
cytokines. Of note, in a cohort of 296 patients with HCC, expression of ERCC1-XPF predicted 
recurrence, metastasis, and death with high significance in TonEBP dependent manner. 
Together, TonEBP is a key component of the common pathway in development, progression, and 
poor prognosis of HCC in response to diverse etiological insults. TonEBP is involved in multiple steps 







Overall Abstract  ----------------------------------------------------------------------------------------------   1 
Contents  --------------------------------------------------------------------------------------------------------  2 
List of figures ----------------------------------------------------------------------------------------------------  4 
Abbreviations ----------------------------------------------------------------------------------------------------  6 
 
Chapter 1. Background  -------------------------------------------------------------------------------------- 9 
1-1. Chronic inflammation and cancer  
1-2. Hepatocellular carcinoma   
1-3. Cancer stem cells   
1-4. Tonicity-responsive Enhancer Binding Protein (TonEBP)  
1-5. References --------------------------------------------------------------------------------------------------- 17 
 
Chapter 2. TonEBP promotes hepatocellular carcinogenesis, recurrence and metastasis 
2-1. Abstract  ---------------------------------------------------------------------------------------------------- 21 
2-2. Introduction  ----------------------------------------------------------------------------------------------- 22 
2-3. Materials and methods  ----------------------------------------------------------------------------------- 23 
2-4. Results  ------------------------------------------------------------------------------------------------------ 28 
2-5. Tables and supplementary tables -------------------------------------------------------------------------- 41 
2-6 Supplementary figures-------------------------------------------------------------------------------------- 49 
2-7 Discussion  ------------------------------------------------------------------------------------------------- 61 




Chapter 3. TonEBP promotes chemoresistance and tumorigenesis of hepatocellular carcinoma 
3-1. Abstract  ---------------------------------------------------------------------------------------------------- 67 
3-2. Introduction  ------------------------------------------------------------------------------------------------ 68 
3-3. Materials and methods  ----------------------------------------------------------------------------------- 70 
3-4. Results  ------------------------------------------------------------------------------------------------------ 74 
3-5. Tables and supplementary tables -------------------------------------------------------------------------- 85 
3-6. Discussion  ------------------------------------------------------------------------------------------------- 90 
3-7. References  ------------------------------------------------------------------------------------------------- 92 
 
Conclusion  ------------------------------------------------------------------------------------------------------ 95 
Graphical summary  -------------------------------------------------------------------------------------------- 97 


















List of Figures and Tables 
 
Figure 1-1. Types of Inflammation in Tumorigenesis and Cancer 
Figure 1-2. Cancer-associated inflammation 
Figure 1-3. Clinical importance of HCC 
Figure 1-4. Pathogenesis of HCC 
Figure 1-5. CSCs-mediated resistance to cancer therapy 
Figure 1-6. RHD of TonEBP and NF-κB 
Figure 1-7. Physiology of TonEBP in hypertonic stress 
Figure 1-8. TonEBP in inflammatory diseases 
Figure 1-9. TonEBP suppresses the PPARγ2 promoter by promoting di-methylation of histone 3 
 
Figure 2-1. Hepatic TonEBP expression is elevated in HCC and associated with postoperative 
recurrence and death in patients with HCC 
Figure 2-2. TonEBP haplo-deficiency is resistant to DEN-induced hepatocarcinogenesis 
Figure 2-3. Promotion of hepatocarcinogenesis by HFD is tempered by TonEBP haplo-deficiency 
Figure 2- 4. Liver injury and inflammation are tempered by hepatocyte-specific TonEBP deficiency 
Figure 2-5. TonEBP-dependent stimulation of COX-2 requires transcription factor YY1 
Figure 2-6. TonEBP and YY1 interact via Rel-homology domain (RHD) and spacer 
Table 2-1. Univariate and multivariate analyses of postoperative recurrence, metastasis, and overall 
survival in patients with HCC (n = 296) 
Table 2-S1. Clinical characteristics of enrolled patients with HCC who received surgical resection 
Table 2-S2. Association of non-tumor TonEBP expression with clinical parameters 
Table 2-S3. Association of tumor TonEBP expression with clinical parameters 
Table 2-S4. TonEBP haplo-deficiency is resistant to DEN-induced liver injury 
Table 2-S5. TonEBP haplo-deficiency is resistant to DEN/HFD-induced liver injury 
Table 2-S6. TonEBP expression was associated with COX-2 expression in patients with HCC 
Figure 2-S1. Hepatic TonEBP expression is elevated in HCC. 
5 
 
Figure 2-S2. Hepatic TonEBP expression is associated with poor postoperative prognosis in patients 
with HCC 
Figure 2-S3. Elevated expression of TonEBP in HCC was associated with a fall in the abundance of 
miR-223 
Figure 2-S4. Expression of TonEBP is associated with inflammation in patients with HCC 
Figure 2-S5. TonEBP promotes oxidative stress-induced cell death and inflammation 
Figure 2-S6. TonEBP-induced paracrine factors promote cell proliferation 
Figure 2-S7. Body weight and blood glucose in animals treated with DEN and fed with HFD 
Figure 2-S8. Signaling and hepatic inflammation in hepatocyte- and myeloid-specific TonEBP 
deficiency 
Figure 2-S9. TonEBP deficiency attenuates inflammation in hepatocytes 
Figure 2-S10. TonEBP stimulates COX-2 expression and PGE2 production 
 
Figure 3-1. TonEBP is required for the self-Renewal of liver cancer stem cells 
Figure 3-2. TonEBP-mediated DNA damage response is greater in cancer stem cells 
Figure 3-3. TonEBP interacts with ERCC1/XPF 
Figure 3-4. ERCC1/XPF is required for the self-Renewal of liver cancer stem cells 
Figure 3-5. TonEBP-mediated DNA damage-induced inflammation is mediated by ATM 
Figure 3-6. ERCC1/XPF-associated poor prognosis is dependent on TonEBP 
Table 3-1. Univariate and multivariate analyses of postoperative recurrence, metastasis, and overall 
survival in patients with HCC (n = 296) 
Table 3-S1. Clinical characteristics of enrolled patients with HCC who received surgical resection 
Table 3-S2. Association of tumor XPF expression with clinical parameters 
Table 3-S3. Association of tumor ERCC1 expression with clinical parameters 









HCC, hepatocellular carcinoma 
CSCs, cancer stem cells 
ATM, ataxia telangiectasia mutated 
Chk1, checkpoint kinase 1 
Chk2, checkpoint kinase 2 
TonEBP, tonicity-responsive enhancer-binding protein 
NFAT, nuclear factor of activated T cells 
NF-κB, nuclear factor kappa B 
RHD, rel-homology domain 
BGT1, betaine-GABA transporter 1 
SMIT, sodium-myoinositol cotransporter 
AR, androgen receptor 
HSP70, heat shock proteins 70 
AP1, activator protein 1 
PPARγ, peroxisome proliferator-activated receptor gamma 
DNMT1, DNA methyltransferase 1 
qRT-PCR, quantitative real-time polymerase chain reaction 
COX-2, cyclooxygenease-2 
HBV, hepatitis B virus 
HCV, hepatitis C virus 
DEN, diethylnitrosamine 
HFD, high fat diet 
ND, normal diet 
LPS, lipopolysaccharide  
D-GalN, d-Galactosamine 
ATCC, american type culture collection 
7 
 
FBS, fetal bovine serum 
MEFs, mouse embryo fibroblasts 
DMEM, dulbecco’s modified eagle’s medium 
IHC, immunohistochemistry 
H&E, hematoxylin and eosin 
FPKM-UQ, quantile normalized FPKM 
GDC, genomics data commons 
ELISA, enzyme-linked immunosorbent assay 
EMSA, electrophoretic mobility shift assay 
ChIP, chromatin immunoprecipitation 
PIVKA II, protein induced by vitamin K absence or antagonist II 
ALT, alanine Aminotransferase 
AST, aspartate aminotransferase 
WT, wild type 
HKO, hepatocyte-specific TonEBP knockout mice 
MKO, myeloid-specific TonEBP knockout mice 
IL-1β, interlukin-1 beta 
TNF-α, Tumor necrosis factor alpha 
PGE2, prostaglandin E2 




MELD, model end stage liver disease 
CTP, Child-Turcotte-Pugh 
CH, chronic hepatitis 
LC, liver cirrhosis 




LDH, lactate dehydrogenase 
ERCC1, Excision Repair Cross-Complementation Group 1 
XPF, xeroderma pigmentation group F 
EPCAM , epithelial cell adhesion molecule 
RPMI, roswell park memorial institute 
FACS, flow cytometry 
UV, ultraviolet 
MMC, mitomycin C 
H2AX, H2A histone family member X 
XPA, xeroderma pigmentation group A 



















Chapter 1. Background 
 
1-1. CHRONIC INFLAMMATION AND CANCER 
Carcinogenesis is initiated by aberrant processing of genomic alterations, followed by promotion and 
progression. Advances in precision medicine including immunotherapy have remarkable advantages 
in outcomes of cancer patients [1]. Despite of advances in treatment, cancer is still a leading cause of 
death and ultimate disease for human survival due to heterogeneous feature.  
 
Figure 1-1. Types of Inflammation in Tumorigenesis and Cancer.  
 
Since environmental cues including inflammation influence the malignancy, tumor 
microenvironment should not be undervalued [2]. Recent findings have suggested pathogenic 
contribution of chronic inflammation in cancer incidence (figure 1-1) [3, 4]. Complex interplay of 
immune cells gives rise to tumor-promoting inflammation and protective response (figure 1-2) [5], 
termed as compensatory proliferation. Protumorigenic transcription factors such as NF-κB, STAT3, 
and AP-1 exert their function on stimulating proliferation of tumor cells by activating downstream 
inflammatory cytokines while interferes tumor suppressor p53 [6]. These transcription factors are 
activated in most cancers. Inflammatory cytokines provide tumor-promoting microenvironment 




Figure 1-2. Cancer-associated inflammation and tumor microenvironment. 
 
In addition, epidemiological studies demonstrated that cancer-associated inflammation gives a 
substantial contribution to poor prognosis including recurrence, metastasis, resistance to 
chemotherapeutic agents, and death [9-11]. Post-therapy poor prognosis represented as metastasis is a 
major cause of cancer-related death [12, 13]. Chronic inflammation is implicated in sequential phases 
of metastasis; epithelial-mesenchymal transition, intravasation, circulating tumor cells, and 
extravasation. Thus, uncovering inflammatory tumor microenvironment is required for improving 
therapeutic outcome. 
 
1-2. HEPATOCELLULAR CARCINOMA (HCC) 
Liver cancer is a common cancer with high mortality: 2nd most leading cause of cancer-associated 
death (< 8 % of 5 year survival rate) and 6th most common malignancy in worldwide (figure 1-3) [14]. 
Lethality of liver cancer driven by combination of multiple factors: inherent resistance to therapeutic 
agents, a lack of early detecting biomarkers, heterogeneous feature, and underlying liver disease 
limiting the use of drugs [15]. Although surgical resection is a conventional effective therapeutic 
strategy, post-operative poor outcomes implicate difficulty of treatment to patients with liver cancer. 
Primary liver cancer is histologically subdivided into hepatocellular carcinoma (HCC), intrahepatic 
bile duct carcinoma (cholangiocarcinoma), hepatoblastoma, bile duct cystadenocarcinoma, 
haemangiosarcoma, and epitheliod haemangioendothelioma [16]. Among these subtypes, HCC is the 
majorly represented types of cancer (> 80% of all cases) [17]. Although incidence of HCC is 
significantly distinguished in a variety of countries, region, and ethnicity, the major etiological hepatic 
insults is associated with chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), chronic 
alcohol consumption, environmental carcinogen such as aflatoxin-B1-contamination (figure 1-4) [18]. 
Although obesity-induced non-alcoholic fatty liver disease positioned at lower frequency, its risk still 
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increase along with growing obese population in worldwide [19]. 
 
Figure 1-3. Clinical importance of HCC. 
 
 HCC is considered as inflammation-associated cancer since chronic inflammation is associated with 
all sequential steps of HCC development. Abnormal proliferative signaling pathway driven by tissue 
damage from infection, environmental cues, or metabolic influences contributes to the malignancy of 
mutated cells (figure 1-3) [20]. Induction of chronic inflammation after tissue damage is consequently 
associated with cirrhosis and promotes hepatocytes necrosis and compensatory proliferation. Thus, 




Figure 1-4. Pathogenesis of HCC. 
 
1-3. CANCER STEM CELLS (CSCs) 
 




Stem cells are required for maintenance of tissue homeostasis. In cancer, tumor initiation and 
maintenance is contributed by a small subset of tumor cells residing in solid tumor with feature like 
stem cells, termed as stem-like cancer cells or cancer stem cells (CSCs) [21, 22]. The capacity of these 
cells is considered to be the source of a new tumor and reconstituted tumor (figure 1-4) [23]. CSCs, 
like tissue stem cells, proliferate slowly and are in dormant G0 phase of cell cycle. Of note, these cells 
have capacity to maintaining genomic integrity like stem cells with high DNA repair capacity by 
elevated genes and protein activity [24]. These features give rise to chemo- or radio-resistance of 
tumor in anti-cancer therapy. The radioresistance of glioblostoma stems from activated ataxia 
telangiectasia mutated (ATM) protein kinase and Checkpoint kinase (Chk) 1 and 2 cancer stem cells 
[25]. 
 As described above, liver cancer develops in the setting of chronic hepatic inflammation promoting 
proliferation of mutated hepatocytes. Chronic inflammation taking place during pathogenesis of HCC 
development induces expansion of progenitor cells and accumulation of genomic instability [26, 27]. 
Inflammatory microenvironment provides niches for the activation of progenitor cells resulting in 
HCC risk [28-30]. The high mortality of HCC patients, a major issue in HCC treatment, stems from 
the high rate of recurrence, tumor heterogeneity, and chemoresistance. Recent studies demonstrated 
that CSCs contributes to these pathological properties [31-33]. Although cell surface markers 
enriching the population of liver CSCs have been identified, underlying molecular basis of 
maintaining self-renewal and tumor-initiating capacity of liver CSCs still remain poor. 
 
1-4. TONICITY-RESPONSIVE ENHANCER BINDING PROTEIN (TonEBP) 
TonEBP, also known as nuclear factor of activated T cells 5 (NFAT5), belongs to the Rel family of 
transcription factors including NF-κB and NFAT 1-4 (figure 1-6) [34, 35]. A variety of molecular and 
physiological functions of TonEBP has been reported. TonEBP was initially identified as a central 
DNA binding transcription factors through rel-homology domain (RHD) as NF-κB in response to 
hypertonic stress by regulating genes such as BGT1, SMIT, AR and HSP70 (figure 1-7) [36, 37]. 
 Recently, we demonstrated that TonEBP functions not only as a transcription factor but also as a 
transcription co-activator in which it bridges activated transcription factor, NF-κB or AP1, to the 
histone acetyltransferase p300 on the gene promoter [38]. In pathological view, expression of TonEBP 
is stimulated by a variety of inflammatory stimuli including hyperglycemia, viral infection, or calorie 
excess. Consequently, TonEBP haplo-deficiency has advantages on the prevention of pathogenesis of 
chronic inflammatory diseases including diabetic nephropathy [39], diabetic retinopathy [40], 
rheumatoid arthritis [41], atherosclerosis [42], encephalomyelitis [43], seizure [44], and obesity-
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Figure 1-7. Physiology of TonEBP in hypertonic stress 
 
 





Figure 1-8. TonEBP in inflammatory diseases 
 
 In addition, we demonstrated that TonEBP suppresses adipogenesis and insulin signaling by 
inhibiting expression of the key transcription factor PPARγ2 (figure 1-9) [45]. TonEBP binds to the 
PPARγ2 promoter and blocks the epigenetic transition of the locus which is required for the activation 
of the promoter. When TonEBP expression is reduced, the epigenetic transition and PPARγ2 
expression are markedly increased leading to enhanced adipogenesis and insulin response while 
inflammation is reduced. 
 Following study revealed that TonEBP is a critical regulator of thermogenesis and obesity. In 
animals with TonEBP haplo-deficiency, high fat diet-induced obesity and metabolic disorder such as 
hyperglycemia, hyperlipidemia, and hyperinsulinemia was ameliorated. TonEBP is required for the 
epigenetic regulation of β3-adrenoreceptor gene, a critical regulator of lipolysis and thermogenesis.  
Recruitment of DNMT1 DNA methyltransferase and methylation of the gene promoter requires 
TonEBP. 
 As described above (1-1), inflammation is recognized as a major contributor of cancer development, 
chemoresistance, recurrence, and metastasis. Although we and others have published that TonEBP is a 
critical regulator of chronic inflammatory diseases, understanding of the role of TonEBP in cancer still 
remain poor. Therefore, uncovering novel molecular basis of cancer by TonEBP implicates providing 
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attractive therapeutic target of cancer treatment. 
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Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. 
Diverse etiological agents and wide heterogeneity in individual tumors impede effective and 
personalized treatment. Tonicity-responsive enhancer-binding protein (TonEBP) is a transcriptional 
cofactor for the expression of pro-inflammatory genes. Although inflammation is intimately 
associated with the pathogenesis of HCC, the role of TonEBP is unknown. We aimed to identify 
function of TonEBP in HCC. Tumors with surrounding hepatic tissues were obtained from 296 
patients with HCC who received completion resection. TonEBP expression was analyzed by 
quantitative RT-PCR and immunohistochemical analyses of tissue microarrays. Mice with TonEBP 
haplo-deficiency, and hepatocyte- and myeloid-specific TonEBP deletion were used along with HCC 
and hepatocyte cell lines. TonEBP expression is higher in tumors than in adjacent non-tumor tissues in 
92.6% of HCC patients regardless of etiology associated. The TonEBP expression in tumors and 
adjacent non-tumor tissues predicts recurrence, metastasis, and death in multivariate analyses. 
TonEBP drives the expression of cyclooxygenease-2 (COX-2) by stimulating the promoter. In mouse 
models of HCC, three common sites of TonEBP action in response to diverse etiological agents 
leading to tumorigenesis and tumor growth were found: cell injury and inflammation, induction by 
oxidative stress, and stimulation of the COX-2 promoter. TonEBP is a key component of the common 
pathway in tumorigenesis and tumor progression of HCC in response to diverse etiological insults. 
TonEBP is involved in multiple steps along the pathway rendering it an attractive therapeutic target as 











Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second most common 
cause of cancer-related death worldwide with steadily increasing incidence [1]. The characteristic high 
mortality of HCC is due to a combination of multiple factors: difficulty in early detection, lack of 
effective treatments, and extremely high rates of recurrence and metastasis [2]. The major etiological 
agents are hepatitis B virus (HBV), hepatitis C virus (HCV), and alcoholic or non-alcoholic fatty liver. 
Genome sequencing, gene expression profiling, and histological analyses have shown that HCC is 
widely heterogeneous and diverse imposing formidable challenges to effective treatment and 
personalized therapy [3, 4]. 
While molecular pathogenesis of HCC is multi-faceted, two sequential mechanisms predominate [5]. 
First is chronic inflammation followed by cirrhosis after tissue damage caused by viral infection, 
alcohol, or metabolic influences. Next come mutations in oncogenes and tumor suppressor genes. 
Thus, a variety of etiological insults incite common cellular reactions creating a microenvironment in 
which sequential mutations and genetic alterations drive formation of dysplastic nodules followed by 
early HCC, and ultimately, metastasis. Investigating the microenvironment might uncover a common 
molecular pathway useful for a prognostic biomarker and therapeutic target. 
Tonicity-responsive enhancer binding protein (TonEBP), also known as NFAT5, is a central 
component of the inflammatory enhanceosome in which TonEBP bridges activated transcription 
factors to histone acetyltransferase p300 on gene promoters [6]. TonEBP expression is stimulated by 
inflammation leading to elevated expression of pro-inflammatory genes in rheumatoid arthritis [7, 8] 
and atherosclerosis [9]. Although several studies have shown that TonEBP is involved in tumor cell 
migration [10], TonEBP’s role in tumor development and progression is unknown. In this study, we 
examined TonEBP in hepatic tissues obtained from HCC patients. We found TonEBP expression to be 
dramatically elevated in tumors than surrounding areas regardless of etiology in over 90% of HCC 
patients confirming the general importance of inflammation. Experiments in animals revealed that 
TonEBP mediates the initial hepatic injury in response to environmental insults leading to local 








2-3. MATERIALS AND METHODS 
Human HCC samples and clinical information 
This research was approved by the Institutional Review Board at the Ulsan University Hospital 
(UUH 2015-12-018). A total of 296 patients who underwent hepatic resection for HCC from January 
2008 to December 2015 at the Ulsan University Hospital, University of Ulsan, College of Medicine, 
Ulsan, Korea, were included in the study. All patients were HCC treatment-naïve before surgery. All 
296 patients who underwent hepatic resection had a grossly complete resection. The patients were 
predominantly males (84.1%) with average age of 56.6 years. The median follow-up period was 31 
months (range = 1-105 months). Postoperative recurrence was observed in 144 cases (48.7%). The 2-, 
5-year HCC recurrence rates were 43.6% and 61.1%, respectively. During postoperative follow-up 
period, metastasis and death were observed in 61 (20.6%) and 84 (28.4%) of cases, respectively. Data 
were expressed as mean +/- standard deviation or median (range). For statistical significance, Student 
t test and chi-squared test were used for comparisons of variables between groups. The cumulative 
relapse and survival rates were evaluated by the Kaplan-Meier method, and differences were 
determined by the log-rank test. A multivariate analysis was carried out to identify the independent 
predictor for recurrence and survival using the Cox regression hazard model. All data were analyzed 
using the statistical package SPSS for Windows (version 21.0; SPSS Inc.). In all cases, a two-tailed P-
value less than 0.05 was considered statistically significant. Additional protocols and procedures are 
described in methods. 
 
Mice 
All the methods involving live mice were carried out in accordance with the approved guidelines. 
All experimental protocols were approved by Institutional Animal Care and Use Committee of the 
Ulsan National Institute of Science and Technology (UNISTACUC-12-15-A). 
All experiments were performed in male C57BL/6 mice. To induce HCC, we administrated a single 
intraperitoneal injection of 25 mg/kg diethylnitrosamine (N0756; Sigma) to 2-week-old mice and 
euthanized them at 9 months of age. In the obesity-amplified DEN-induced HCC model, DEN (25 
mg/kg) was injected intraperitoneally (i.p.) into 2-week-old mice. After 4 weeks, mice were separated 
into two dietary groups and fed either normal diet (ND, 10% fat as kcal, Research Diets, NJ, USA) or 
high fat diet (HFD, 60% fat as kcal, Research Diet) and euthanized for 36 weeks dietary period. 
Tumor incidence and size were blindly calculated.  
C57BL/6 TonEBPf/f mice [11] were bred with Alb-Cre mice or LysM-cre to generate 
24 
 
TonEBPf/f:Alb-Cre or TonEBPf/f:LysM-Cre, respectively. To induce liver injury, TonEBPf/f:Alb-Cre or 
TonEBPf/f:LysM-Cre mice and their WT littermates were intraperitoneally injected single DEN 
(100mg/kg) and euthanized after 48 hrs. For LPS-induced liver injury, TonEBPf/f:Alb-Cre mice were 
intraperitoneally co-injected of LPS (5 g/kg of body weight) and D-GalN (400 mg/kg of body weight) 
and euthanized after 4 hrs. 
Ethanol feeding-induced liver injury and fat accumulation was demonstrated as described [12]. 
Briefly, mice were acclimated liquid diet feeding with the control Lieber-DeCarli diet (Bio-Serv) ad 
libitum for 5 days, followed by ethanol Lieber-DeCarli diet (Bio-Serv) containing 5% (vol/vol) 
ethanol supplemented with maltose dextrin or isocaloric control diet for 10 days. To synergistically 
inducing liver injury and inflammation, on day 11, mice were gavaged with a single dose of ethanol (5 
g/kg) or isocaloric dextrin-maltose at 8 am, and sacrificed 9 hours later.  
 
Cell line 
HCC cell line, HepG2, from American Type Culture Collection (ATCC) was maintained in 
modified Eagle's medium (MEM, Hyclone) supplemented with 10% fetal bovine serum (FBS; 
Thermo) with penicillin-streptomycin (Hyclone). Cells were transfected with TonEBP siRNA or 
control scrambled siRNA using lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s 
instructions. Cells were transfected miRNA-223 or control miRNA using lipofectamine 2000 
(Invitrogen) following the manufacturer’s instructions. Mouse embryo fibroblasts (MEFs) and 
HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% FBS (Thermo) with penicillin-streptomycin (Hyclone). MEFs were established from the 
TonEBPΔ/Δ mouse. For binding assays, HEK293 cells were transfected plasmids using lipofectamine 
2000 (Invitrogen) following the manufacturer’s instructions. For hypoxia challenge, HepG2 cells were 
incubated in hypoxic chamber in 2% O2. Additional protocols and procedures are described in 
methods. 
 
Immunohistochemistry (IHC) and histology analysis 
Liver tissues were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 5 
μm sections. Paraffin sections were deparaffinized and dehydrated. Antigen of TonEBP and COX-2 
was retrieved by citrate and peroxidase and that of Ki-67 was retrived by EDTA and peroxidase in 
appropriate time for each antigen. Anti-ki-67 antibodies (12202T, CST), anti-COX-2 antibodies (SP21, 





Human HCC patient tissue samples were collected as previously described. H&E of each patient 
was analyzed by histologist and representative paired hepatic tumor and adjacent non-tumor region of 
296 HCC patients in formalin-fixed paraffin-embedded tissue was marked and extracted for tissue 
array. Then, extracted tissue was arranged, molded by using tissue microarray cassette, and solidified 
for tissue array analysis. The arrays were processed simultaneously for TonEBP 
immunohistochemistry and signal intensity was assigned to five grades (t0 to t4) using an image 
software (Image J). 
 
TCGA analysis 
Upper Quantile normalized FPKM (FPKM-UQ) of RNA-seq and matched clinical information of 
HCC cohorts was extracted from metadata of TCGA of Genomics Data Commons portal (https://gdc-
portal.nci.nih.gov). With R studio, the transcript level of TonEBP and inflammatory genes was 
analyzed in HCC patients who have RNA-seq dataset from both tumor and matched non-tumor in 
GDC (n = 100). Correlation analysis between TonEBP and inflammatory genes were generated using 
R-derived RNA-seq and plotted with Graphpad Prizm.  
 
Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated using the TRIzol reagent (Invitrogen) followed by chloroform and ethanol 
precipitation. cDNA was synthesized by M-MLV reverse transcriptase (Promega) according to the 
manufacturer’s instructions. After reverse transcription, Q-PCR was performed using SYBR Green I 
Master and LightCycler 480 II (Roche). Measured cycle threshold values were normalized with 
GAPDH and they were expressed as fold-over control samples. All qRT-PCR reactions were 
duplicated. Adequacy of GAPDH as a house keeping gene was confirmed by NormFinder. 
 
Immunoblotting 
Cell lysis for protein extraction was performed as previously described. Protein concentration was 
measured by BCA system (Pierce). Equal amounts of protein from each sample were separated by 
SDS-PAGE and immunoblotted using specific primary antibodies. HRP-conjugated secondary 
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antibodies were used for detection. The antigen-antibody binding was detected by enhanced 
chemiluminescence Western blotting detection reagents (GE healthcare life sciences). Anti-YY1 
antibodies(13G10, Cell Signalling Technologies (CST)), COX-2(4842, CST), anti-myc-tag(2278, 
CST), anti-flag antibodies (F1804, Sigma Aldrich), p300 (sc584, SantaCruz Biotechnology), LaminB 
(sc6217, SantaCruz Biotechnology) antibodies, anti-Hsc70 (200-301-A28, Rockland) and anti-
TonEBP antibody 40 were used for immunoblotting. 
 
ELISA 
IL-1β-stimulated human prostaglandin E2 in supernatants from HepG2 cells was analyzed with 
ELISA kits (R&D Systems). Prostaglandin E2 in serum from animal experiments was analyzed with 
ELISA kits (Abcam) 
 
Promoter and Reporter assay 
Human COX-2 promoter fragments were inserted into pGL3 (Promega). Human genomic DNA 
fragment covering nucleotide positions -2,460 to +83 relative to the transcription start site of the 
COX-2 gene, including a TonE (TonEBP binding site) at nucleotide position -2,282, was cloned and 
placed in a promoter-less luciferase reporter (pGL3) to produce a COX-2 promoter reporter named 
“COX-2 2.5kb”. TonEBP binding sites or YY1 binding sites in COX-2 promoter was mutated using 
cloned COX-2 promoter with primers and indicated as ΔTonE or ΔYY1. YY1 has a putative binding 
site at nucleotide position -546 from the transcription start site. Cells were transfected luciferase 
plasmid. The Renilla luciferase reporter plasmid (pRL-TK, Promega) was used as a control for 
transfection efficiency. Luciferase activity after 6 h of stimulation was measured using the Dual-
Luciferase Assay System (Promega) according to the manufacturer’s instructions. Luciferase activity 
was normalized by activity of renilla luciferase. Luciferase activity was expressed relative to pGL3 
transfected cells (figure S11A) or relative to non-treated, pGL3 transfected cells (figure 5G). 
To verify the binding of miRNA-223 to the predicted site in 3-UTR region of TonEBP gene, 
predicting algorithms in Targetscan (www.targetscan.org) and psiCHECK-2 vector was used. 300-bp 
region of the predicted miR-223 binding site in 3’-UTR of TonEBP gene was cloned into a 
psiCHECK-2 (Promega) downstream of the Renilla luciferase–coding region. To validate the effects 
of miR-223, HEK293 cells were transfected miR-223 or NC, followed by transfection of a reporter 
construct. Luciferase activity after 48 h of transfection was measured using the Dual-Luciferase Assay 
System (Promega) according to the manufacturer’s instructions. Luciferase activity was normalized 
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by activity of renilla luciferase.  
 
Nuclear and Cytoplasmic fractionation 
Cells were harvested by using scrapper and centrifuged. The cell pellet was washed by suspension 
with PBS. The cell nucleus and cytoplasm were separated by using Nuclear and Cytoplasmic 
extraction kit (Pierce) according to manufacturer’s instruction.  
 
Electrophoretic mobility shift assay (EMSA). 
A commercial kit was used: Lightshift Chemiluminescent EMSA kit (Pierce). Nuclear extracts were 
incubated with poly(dI:dC), binding buffer and 5′ biotinylated DNA, containing the YY1 binding site 
in the COX-2 promoter, at room temperature for 20 min. Samples were separated by electrophoresis 
for 4 h in 4% (40% 29:1 acrylamide/bis solution) gel for TonEBP and 8% gel for YY1. The detection 
was performed according to manufacturer’s instructions.  
 
Chromatin immunoprecipitation 
ChIP was performed as previous studies. In brief, cells were crosslinked with 1% formaldehyde 
followed by addition of 125 mM glycine. After washing, cells were sonicated and immunoprecipitated 
with normal serum, anti-TonEBP and anti-YY1 (Abcam) antibodies at 4 ˚C overnight. After elution 
and reverse crosslinking the antibody/DNA complexes, DNA was purified by DNA purification kit 
(Qiagen) and analyzed by q-PCR using primer pairs covering specific region of the COX-2 promoter 
in duplicates. 
 
Cell Death assays 
Death of primary hepatocytes in vitro was estimated using an LDH release-based cytotoxicity assay 
(Promega) after incubating primary hepatocytes for 24 hr in the absence or presence of hypoxic 






 Data are presented as means + SD or +SEM as indicated. Differences between groups were analyzed 
by student’s t-test, and statistically significance was considered at *p < 0.05. 
2-4. RESULTS 
Hepatic TonEBP predicts postoperative prognosis in HCC patients 
 
Figure 2-1. Hepatic TonEBP expression is elevated in HCC and associated with postoperative 
recurrence and death in patients with HCC. (A–D) Hepatic TonEBP expression in a mouse 
model of HCC. (A) TonEBP mRNA levels in tumor-free normal tissues from PBS-injected animals 
(n = 8), and non-tumor and tumors from DEN-injected animals (n = 18). Mean + SEM, *p < 0.05. 
(B) Immunoblots of non-tumor and tumors from 7 animals. (C) Immunohistochemical images of 
TonEBP (brown) in hepatic tissues from PBS- or DEN-injected animals. NT, non-tumor; T, tumor. 
Nuclei were counterstained with hematoxylin (blue). (D) Tumor number and TonEBP mRNA in 
non-tumor in individual animals were plotted. n = 12. (E-G) TonEBP expression in hepatic tissues 
of HCC patients. (E) Representative Immunohistochemical images of TonEBP in hepatic biopsies 
from HCC patients. (F) TonEBP mRNA in non-tumor and tumor were measured from patients with 
HBV- (n = 23), HCV- (n = 7), alcohol-associated HCC (n = 8). Tumor TonEBP expression of each 
patient was normalized to its non-tumor region TonEBP expression. Mean + SEM, *p < 0.05 
compared to corresponding non-tumor. (G) Non-tumor TonEBP mRNA were measured from 
patients who had recurrence within 2 years of resection (solid bar, n = 16) and those who did not 
(open bar, n = 21). Mean + SEM, *p < 0.05 compared to the open bar. (H) Representative images of 
TonEBP immunohistochemical staining of non-tumor from tissue arrays processed simultaneously. 
Staining intensity was assigned to five grades as shown (t0 – t4). (I) Kaplan-Meier plot of 
postoperative recurrence in two layer of patients: tNT0 (t0, n=130) vs. tNT1 (t1-t4, n=166) (J) 
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Kaplan-Meier plot of postoperative survival in two layer of patients tT0 (t0-1, n=80) vs. tNT1 (t2-4, 
n=216) (K) HEK293 cells were transfected miR-223 or non-specific control RNA (NC), followed 
by transfection of a luciferase reporter construct containing 3′-UTR of TonEBP with a putative miR-
223–binding site. Luciferase activity is shown in mean + SD, n = 3. *p < 0.05 compared to NC. (L) 
HepG2 cells were transfected with miR-223 or NC followed by a 12 h hypoxia or normoxia. 
TonEBP and Hsc70 immunoblotting was performed. 
 
In macrophages TonEBP expression is markedly stimulated by inflammatory signals6. Since 
inflammation is an essential feature of HCC [13, 14], we investigated hepatic TonEBP expression in 
diethylnitrosamine (DEN)-induced mouse HCC. Expression of TonEBP mRNA in non-tumor regions 
surrounding tumors (non-tumor TonEBP mRNA expression) was higher compared to normal hepatic 
tissues, while lower compared to adjacent tumor (figure 1A). TonEBP expression was higher in 
tumors compared to non-tumor regions and localized to the nuclei of hepatocytes (figure 1B,C and 
S1A). Interestingly, non-tumor TonEBP mRNA expression correlated significantly with tumor 
numbers (figure 1D) consistent with the importance of inflammation in HCC. 
We examined hepatic tissues obtained from 296 HCC patients (table S1). As in the animals, TonEBP 
mRNA expression was higher in tumors compared to non-tumor regions (figure S1B). 
Immunohistochemical analyses (figure 1E and figure S1C) revealed the same pattern of changes in 
92.6% of the patients (274/296). This elevation was observed regardless of etiology (figure 1F). 
Interestingly, non-tumor TonEBP mRNA expression was higher in patients who had early recurrence 
compared to patients who did not (figure 1G). These observations suggest importance of TonEBP in 
tumorigenesis, and that non-tumor TonEBP promotes post-operative recurrence. 
Given the importance of TonEBP, we investigated the role of TonEBP further by stratification of the 
patients according to their TonEBP expression (figure 1H). Univariate analysis of two layers of 
patients showed that higher non-tumor TonEBP expression was significantly associated with bigger 
tumor, advanced tumor grade, recurrence, metastasis (i.e., extrahepatic metastasis), and protein 
induced by higher vitamin K absence or antagonist II (PIVKA II) and HBV DNA level (table S2). 
Kaplan-Meier plot confirmed the higher recurrence (figure 1I) and metastasis (figure S2A) in patients 
with higher non-tumor TonEBP expression. Likewise, higher tumor TonEBP expression was 
associated with advanced tumor grade, microvascular invasion, recurrence, metastasis, death, and 
higher PIVKA II level (table S3). Again, Kaplan-Meier plot confirmed the lower survival (figure 1J), 
and higher metastasis and recurrence (figure S2C,D) in patients with higher tumor TonEBP expression. 
These observations suggest that TonEBP promotes various aspects of tumorigenesis and progression. 
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We further investigated TonEBP’s role in post-operative prognosis by multivariate analyses. As for 
recurrence, tumor size, microvascular and lymphovascular invasion along with non-tumor TonEBP 
expression displayed strong association (table 1). Male sex, ALT levels, albumin levels, tumor size, 
tumor grade, microvascular invasion, and non-tumor TonEBP expression showed robust association 
with metastasis. Finally, microvascular invasion, albumin levels, and TonEBP expression in tumor 
were significantly associated with overall survival. We conclude that hepatic TonEBP expression 
predicts post-operative recurrence, metastasis, and death in HCC patients. 
 
Hepatic induction of TonEBP is mediated by a fall in the miR-223 abundance 
Elevated TonEBP expression is critical for the HCC development and progression. Previous studies 
showed that miR-223 expression was dramatically suppressed in HCC regardless of etiology [15], 
likely due to local hypoxia (figure S3A) [16, 17]. As expected, miR-223 abundance was reduced in 
tumor regions compared to non-tumor regions in HCC patients (figure S3B) and DEN-induced HCC 
(figure S3C). Since TonEBP gene is a target of miR-223 in mouse macrophages [18], we asked 
whether the hypoxia-mediated fall in miR-223 abundance was responsible for the elevated TonEBP 
expression. miR-223 interacted with the 3’-untranslated region of human TonEBP mRNA (figure 1K) 
and lowered the abundance of TonEBP (figure S3D,E) both in normoxia and hypoxia (figure 1L). 
Thus, suppression of miR-223 contributes to the elevated expression of TonEBP in HCC. 
 
TonEBP promotes HCC initiation and growth via oxidative stress and inflammation 
 Since hepatic TonEBP expression was closely associated with the number of tumors in a mouse 
model of HCC (figure 1D), we next investigated the role of TonEBP in HCC using a line of mice with 
TonEBP haplo-deficiency – TonEBP+/Δ (figure 2A) [19]. Number of tumors and maximal tumor size 
were both significantly smaller in the TonEBP+/Δ animals than their TonEBP+/+ littermates (figure 
2B,C) in association with reduced liver injury (table S4). Histological examinations typically revealed 
smaller tumors (figure 2D-(i)), smaller dysplastic nodules (figure 2D-(ii)), and often absence of 
tumors (figure 2D-(iii)) in the TonEBP+/Δ animals. Since chronic inflammation leads to cirrhosis 
followed by HCC [20], we examined hepatic inflammation. Expression of pro-inflammatory and 
angiogenic genes was strikingly elevated in HCC mice along with TonEBP (figure 2E) indicating the 
association of elevated TonEBP expression with inflammation. As expected, expression of these genes 
was significantly lower in the TonEBP+/Δ animals indicating that TonEBP promoted tumor initiation 
and growth in association with inflammation and liver injury. In HCC patients, the association 




DEN causes oxidative stress [21] leading to hepatic cell death which, in turn, evokes local 
inflammation [22, 23]. TonEBP was induced by hypoxia (figure 1M) and H2O2 (figure S5A). 
Knockdown of TonEBP reduced cell injury (figure S5B,C) and inflammation (figure S5D) in response 




Figure 2-2. TonEBP haplo-deficiency is resistant to DEN-induced hepatocarcinogenesis. 
TonEBP+/Δ mice and their TonEBP+/+ littermates were treated with PBS or DEN as in figure 1. (A) 
Non-tumor regions adjacent to tumors were immunoblotted for TonEBP and Hsc70 from DEN-
injected animals. (B) Representative liver images from DEN-injected animals. (C) Tumor number, 
maximal size of tumors, and liver weight from PBS- (n = 8 for each genotype) or DEN-injected 
mice (n = 18 for each genotype). Mean + SEM. #p < 0.05 compared to corresponding PBS-injected 
animals. *p < 0.05 compared to DEN-injected TonEBP+/Δ animals. (D) Representative H&E images 
of hepatic tissues from DEN-injected animals. Magnified images on the right are from small boxes 
on the left. Boxes are in tumors (top and bottom of (i), and top of (ii) and (iii)), dysplastic nodule 
(bottom of (ii)), or tumor-free area (bottom of (iii)). (E) RT-qPCR analyses of TonEBP, 
inflammatory genes (COX-2, TNFα, IL-1β, IL-6, MCP-1), macrophage marker (F4/80), 
proliferation markers (Ki-67, cyclin D1), and angiogenic factors (HIF-1α, VEGF) in non-tumor 
regions adjacent to tumors in animals from C. (F) Representative immunohistochemical images of 
TonEBP and Ki-67. 
 
We noted that proliferation markers were elevated in the mouse model of HCC (figure 2E,F). 
Inflammatory cytokines are known to promote tumor growth. Interestingly, manipulation of TonEBP 
expression led to parallel changes in proliferation of HepG2 cells (figure S6B,C). Over-expression of 
TonEBP stimulated proliferation of neighboring naïve cells (figure S6D,E) suggesting that paracrine 
factors contributed to the TonEBP-dependent stimulation of proliferation. These results provide 
mechanistic basis for the role of TonEBP on the tumor growth. We conclude that TonEBP promotes 
tumor initiation and growth via oxidative stress-induced cell injury and inflammation. 
 
TonEBP is involved in obesity-induced tumor initiation and growth 
 Epidemiological studies have shown that obesity increases cancer risk [24-26]. Obesity-induced 
chronic inflammation is a major factor contributing to the increased HCC risk [27]. Because the data 
discussed above showed that TonEBP promoted tumor initiation and growth via inflammation, we 
examined obesity-induced HCC (figure S7A). TonEBP+/Δ animals were lighter than their WT 
littermates both in DEN- and PBS-treated groups up to the 12th week of HFD feeding (figure S7B). In 
the DEN-treated group, distinct change took place. After the 26th week, there was a reversion where 
the TonEBP+/Δ became significantly heavier than their WT littermates because of smaller weight loss. 
During the reversal of body weight, high blood glucose levels in the WT littermates disappeared 
(figure S7C,D). These changes are likely due to differences in tumor burden. 
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HFD feeding increased hepatic non-tumor TonEBP expression (figure 3A) along with more and 
bigger tumors (figure 3B–D), elevated expression of pro-inflammatory genes, proliferation markers 
(figure 3E), and liver injury (table S5). TonEBP haplo-deficiency was associated with fewer and 
smaller tumors, reduced expression of pro-inflammatory genes (which correlated with expression of 
TonEBP (figure 3F)) and proliferation markers, and milder liver injury expression providing strong 
evidence that TonEBP is involved in the obesity-induced inflammation and hepatocellular 
carcinogenesis. 
 
Figure 2-3. Promotion of hepatocarcinogenesis by HFD is tempered by TonEBP haplo-
deficiency. Animals were injected with DEN as in figure 2, followed by feeding with ND or HFD 
for 30 weeks (figure S4). (A) Non-tumor regions adjacent to tumors were immunoblotted for 
TonEBP and Hsc70 in TonEBP+/+ animals. (B) Representative liver images. (C) Top: Tumor 
number, maximal tumor size, and maximal tumor weight from individual animals fed with ND (n = 
12 for each genotype) or HFD (n = 15 for each genotype). Mean + SEM, *p < 0.05 compared to 
corresponding TonEBP+/+. #p < 0.05 compared to corresponding ND. Bottom: Tumors larger than 3 
mm in diameter from representative individual animals are shown. (D) Representative images of 
H&E stained liver tissues from animals fed with HFD. (E) RT-qPCR analyses as in figure 2E. (F) 
Correlation of TonEBP mRNA expression with mRNA expression of COX-2, TNFα, and MCP-1 in 
non-tumor areas of hepatic tissues from TonEBP+/+ animals fed with ND (n = 10) and HFD (n = 10). 
 
TonEBP in hepatocytes and macrophages mediates DEN-induced cellular injury and 
inflammation 
 The data discussed above show that TonEBP promotes inflammation critical in tumor initiation and 
growth. Since DEN results in cellular injury leading to inflammation and eventually HCC [21], we 
examined TonEBP’s role in hepatic injury using a line of mice with hepatocyte-specific TonEBP 
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knockout (HKO) [11]. Hepatic TonEBP expression, especially TonEBP immunohistochemical signal 
in hepatocytes, was dramatically reduced in these animals (figure S8A,B). In WT mice, hepatic 
TonEBP is elevated 48h after DEN treatment (figure 4A) consistent with oxidative injury. DEN-
induced hepatic injury was reduced in the HKO animals compared to WT littermates (figure 4B), 
manifested by lower TUNEL signal (figure 4C) and caspase-3 activity (figure 4E). Expression of Ki-
67 and PCNA was significantly lower in the HKO after DEN treatment along with pro-inflammatory 
genes (figure 4D,E). Phosphorylation of MAPKs was not affected (figure S8C) indicating that 
upstream signaling was not affected in the HKO. Taken together, hepatocyte TonEBP mediates DEN-
induced hepatic injury and inflammation. 
Figure 2-4. Liver injury and inflammation are tempered by hepatocyte-specific TonEBP 
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deficiency. (A–D) TonEBPfl/fl; Albumin cre+/- mice (HKO) and their TonEBPfl/fl; Albumin cre-/- (WT) 
littermates were injected with DEN or PBS. Livers and serum samples were analyzed 48 h later. (A) 
Livers from the WT animals were immunoblotted for TonEBP and Hsc70. (B) Serum ALT levels in 
PBS- (n = 5) and DEN-treated animals (n = 8). Mean + SEM. *p < 0.05 compared to WT. (C) 
TUNEL signal in hepatic tissues. (D) RT-qPCR analyses of TonEBP, inflammatory genes (COX-2, 
TNFα, IL-1β, IL-6), and proliferation markers (Ki-67, cyclin D1) in livers of DEN treated animals. 
mRNA abundance was expressed relative to WT group. P, PBS; D, DEN. Mean + SEM, #p < 0.05 
compared to corresponding P. *p < 0.05 compared to WT. (E) Immunoblotting of liver samples, 3 
from each genotype, for TonEBP, PCNA, Hsc70, caspase-3, cleaved caspase-3 (C-Casp-3), COX-2, 
and iNOS. (F,G) HKO and WT animals were injected with PBS or LPS (5 μg/kg) in combination 
with D-galactosamine (400 mg/kg) (LPS). The animals were analyzed 4 h later. (F) Serum levels of 
ALT and AST. (G) RT-qPCR analysis mRNA levels. mRNA abundance was expressed relative to 
WT, PBS group. Mean + SEM, *p < 0.05 compared to WT. # p < 0.05 compared to PBS. (H–J) The 
animals were fed with control diet (Con) or ethanol diet (EtOH) for 10 days. (H) Serum ALD, AST, 
and LDH levels. *p < 0.05 compared to WT. #p < 0.05 compared to corresponding control diet-fed 
animals. (I) qRT-PCR analyses of TonEBP and inflammatory genes in livers. (J) Representative 
images of H&E of hepatic tissues from animals from (H). (K) Changes in body weight and food 
intake levels after switch to ethanol diet. (L-O) HKO (n = 11) and WT (n = 10) animals were fed 
with high fat diet (HFD) for 16 weeks. (L) Changes in body weight and fasting blood glucose levels 
after switch to HFD. Glucose tolerance after 8 weeks on HFD (n = 8). (M) Serum concentration of 
insulin level. (N) Calculated HOMA-IR from (M). (O) RT-qPCR analyses of TonEBP, inflammatory 
in epididymal (Epi) white adipose tissue. 
 
As TonEBP is a critical regulator of the pro-inflammatory activation of macrophages [6, 28], we 
examined the role of macrophage TonEBP using a line of mouse with myeloid-specific TonEBP 
knockout (MKO) [6]. These animals displayed normal TonEBP expression in hepatocytes (figure 
S8D). DEN-induced hepatic injury, inflammation, and proliferation were reduced in the MKO 
compared to WT littermates (figure S8E,F). These data demonstrate that macrophage TonEBP also 
contributes to the DEN-induced hepatic injury and inflammation.  
 
TonEBP mediates LPS- and fatty liver-induced hepatic inflammation  
We asked whether TonEBP mediates inflammation induced by agents other than DEN. First, we 
examined lipopolysaccharide (LPS) which leads to hepatocyte death and inflammation [29]. LPS-
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responsive hepatic injury (figure 4F) and inflammation (figure 4G) were tempered in the HKO. The 
effect of TonEBP on LPS-induced inflammation was confirmed in HepG2 cells (figure S9A). 
Alcohol causes leakage of LPS from gut into circulation leading to hepatic inflammation [30]. Since 
alcoholic hepatitis is a risk factor for HCC [31] and TonEBP mediates LPS-induced hepatocyte 
inflammation as discussed above, the role of TonEBP in alcohol-induced hepatic injury was examined. 
The chronic and binge alcohol feeding resulted in hepatic damage, inflammation, and fat 
accumulation (figure 4H–J). Hepatic inflammation and injury were reduced in the HKO animals 
(figure 4H,I) without significant changes in fat accumulation (figure 4J), body weight, and food intake 
(figure 4K). These data demonstrate that hepatocyte TonEBP mediates alcohol-induced hepatic injury 
and inflammation to which the TonEBP-mediated LPS-responsive hepatic inflammation described 
above contributes. 
To understand the role of TonEBP in hepatic inflammation in general, we analyzed inflammatory 
stimuli-responsive inflammation. IL-1β- or TNF-α-induced inflammation was attenuated in TonEBP-
deficient HepG2 cells (figure S9B,C) and non-cancerous AML-12 cells (figure S9D).  
We next examined function of hepatic TonEBP in obesity-induced systemic metabolic disorder by 
high fat diet (HFD; 60% energy as fat) feeding. Hepatic TonEBP deficiency lowered fasting blood 
glucose level and improved glucose tolerance while body weight displayed no changes compared to 
WT animals (figure 4L). As expected, serum insulin level and HOMA-IR were reduced in HKO 
animals (figure 4M,N). To investigate the systemic effects of hepatic TonEBP deficiency in obesity, 
we analyzed adipose tissue inflammation. As previous observation, epididymal white adipose tissue is 
inflamed by HFD feeding. Inflammation in adipose tissue was lowered in HFD-fed HKO animals 
compared to WT animals (figure 4O), indicating that hepatic TonEBP deficiency reduces systemic 
inflammation. Taken together, these data demonstrate that TonEBP is a general mediator of hepatic 
inflammation induced by diverse agents, consistent with elevated TonEBP expression regardless the 
cause of HCC (figure 1G). 
 
TonEBP promotes COX-2 expression in an YY1-dependent manner 
 Transcriptional targets of the inflammatory enhanceosome, in which TonEBP is a limiting 
component, include cyclooxygenase-2 (COX-2) [6]. We investigated COX-2 because it promotes 
tumorigenesis [32-34], and COX-2 expression in HCC patients correlates with post-operative 
recurrence [35] like TonEBP. In HCC patients, COX-2 expression was elevated in tumor regions 
compared to non-tumor regions (figure S10A). TonEBP expression correlated positively with COX-2 
expression (figure 5A,B and table S6). TonEBP deficiency resulted in reduced COX-2 expression 
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(figure 5C,D and figure S10B,C) leading to reduced production of prostaglandin E2 (PGE2) in 
various animal models (figure 5E and figure S10D-F) and HepG2 cells (figure S10G). Altered 
TonEBP expression by hypoxia and miR-223 was accompanied by parallel changes in the COX-2 
expression (figure S10H). In addition, the TonEBP-dependent stimulation of proliferation (figure 
S6D,E) was dependent on COX-2 (figure S10I). These data demonstrate that TonEBP promotes 
tumorigenesis and recurrence by, at least in part, the stimulation of COX-2 expression. 
 
Figure 2-5. TonEBP-dependent stimulation of COX-2 requires transcription factor YY1. (A) 
TonEBP vs. COX-2 mRNA abundance in tumors from 25 HCC patients. (B) Immunohistochemical 
images of COX-2 and TonEBP in consecutive hepatic sections from two representative HCC 
patients. (C) Immunoblots of livers from TonEBP+/Δ (+/Δ) and their TonEBP+/+ littermates (+/+) 
from figure 2A. (D) Immunoblots of HepG2 cells transfected with siRNA followed by treatment 
with IL-1β. (E) Serum PGE2 levels in PBS- (n = 5) or DEN-treated mice (n = 8 for each genotype) 
from figure 2.. Mean + SEM. *p < 0.05 compared to TonEBP+/+. #p < 0.05 compared to PBS-
injected mice. Serum PGE2 levels in Mean + SEM. *p < 0.05 compared to DEN-injected TonEBP+/Δ 
animals. (F) Lysates of HepG2 cells treated with IL-1β or not (con) as indicated were 
immunoprecipitated (IP) with normal IgG, anti-YY1 IgG (YY1), normal serum (S), or anti-TonEBP 
serum (T). The immunoprecipitates and cell lysates were immunoblotted as indicated. (G) HepG2 
cells were transfected with siRNA indicated followed by transfection with pGL3 (vector), COX-2 
(COX-2 promoter reporter in pGL3), or ΔYY1 (COX-2 whose YY1 binding site was disabled by 
mutagenesis). n = 3. (H) HepG2 cells were treated with IL-1β as indicated. Chromatin 
immunoprecipitation (ChIP) was performed using anti-TonEBP IgG, anit-YY1 IgG, or normal IgG. 
YY1 binding region in the COX-2 promoter was quantified using qPCR. Means of 2 independent 
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experiments are shown. (I) HepG2 cells were transfected with siRNA and treated with IL-1β. ChIP 
was performed with anti-YY1 IgG. Means of 2 independent experiments are shown. (J) Nuclear 
extracts were prepared from HepG2 transfected with siRNA followed by treatment with IL-1β as 
indicated. Electrophoretic mobility shift assay was performed (see methods). Anti-YY1 IgG or 
normal IgG was used to supershift the YY1-DNA complex (right). (K) Lysates of HepG2 cells 
treated with IL-1β were immunoprecipitated. Lysates and immunoprecipitates were immunblotted 
for p300 and YY1. (L) Cells transfected with siRNA were immunoprecipitated as above. (M) MEFs 
from TonEBP+/+ (+/+) and TonEBPΔ/Δ mouse (Δ/Δ) were immunoprecipitated.  
 
To understand the molecular mechanism underlying the regulation of COX-2, promoter reporters 
were constructed using human sequence. Initial analyses showed that TonEBP stimulated the COX-2 
promoter without DNA binding to its cognate sites (figure S11A,B). We hypothesized that TonEBP 
might be a transcriptional co-factor of a DNA binding protein within 1kb from the transcription start 
site. To identify such a protein, TonEBP-interacting proteins were identified using liquid 
chromatography-tandem mass spectrometry. One of the proteins picked by the procedure was the 
transcription factor YY1 (data not shown). We confirmed that YY1 and TonEBP were mutually co-
immunoprecipitated; plus the interactions were stimulated by IL-1β without changes in their 
expression (figure 5F). Knockdown of TonEBP or YY1 blunted the induction of COX-2 mRNA by 
IL-1β to the same extent, but the effect of double knockdown was not additive (figure S11C). 
TonEBP-dependent COX-2 promoter activity was dependent on the YY1 binding site (figure 5G) 
demonstrating that TonEBP action required DNA binding of YY1. 
 
TonEBP promotes YY1 recruitment to the COX-2 promoter in response to inflammation 
Chromatin immunoprecipitation (ChIP) was performed to investigate the interaction of YY1 and 
TonEBP at the COX-2 promoter in situ. Interestingly, YY1 bound to its putative binding site of the 
COX-2 promoter in an IL-1β-dependent manner along with TonEBP (figure 5H) consistent with their 
interactions. Knockdown of TonEBP dramatically reduced of YY1 binding to the promoter (figure 5I), 
whereas YY1 expression (figure S11D), nuclear translocation (figure S11E), and binding to its 
promoter site (figure 5I) were not affected. Thus, YY1 binding to its cognate site in the COX-2 
promoter requires TonEBP. 
TonEBP is responsible for the recruitment of the histone acetyltransferase p300, a critical regulator 
of COX-2 transcription [36], to the inflammatory enhanceosome. Here we found that YY1 interacted 
with p300 in HepG2 cells and the interaction showed an IL-1β-responsiveness (figure 5K) as well as 
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TonEBP-dependence (figure 5L) indicating that YY1 was incorporated into the inflammatory 
enhanceosome on the COX-2 promoter. This observation was supported by reduced interaction 
between YY1 and p300 in TonEBPΔ/Δ mouse embryonic fibroblast (MEF) cells where the protein 




Figure 2-6. TonEBP and YY1 interact via Rel-homology domain (RHD) and spacer. (A) 
Diagrams of TonEBP and YY1 and their deletion constructs. (B-E) Lysates from HEK293 cells 
transfected with Myc-TonEBP plus Flag-YY1 (B) or various recombinant fragment of Flag-YY1 (C) 
Myc-Yc1 plus or Flag-YY1 or Flag-YY1ΔS (D) or Flag-YY1 plus Myc-TonEBP or Myc-TonEBP 
ΔRHD (E) were immunoprecipitated (IP) with normal IgG (IgG), anti-Flag IgG (Flag), or anti-Myc 
IgG (Myc) as indicated. The immunoprecipitates (upper) and lysates (bottom) were immunoblotted 
as indicated. (F) Model of TonEBP actions in the pathogenesis of HCC. First, TonEBP mediates 
oxidative stress-induced cell injury and local inflammation. Second, TonEBP expression is enhanced 
by oxidative stress. On the promoter of the COX-2 gene, the elevated TonEBP recruits the 
acetyltransferase p300 to YY1 in a manner dependent on IL-1β. TonEBP promotes tumorigenesis, 
recurrence, and metastasis via PGE2 and possibly other pathways (broken line). See text for details. 
 
To characterize the interaction between TonEBP and YY1, we performed co-immunoprecipitation 
experiments. Overexpressed TonEBP and YY1 were mutually pulled down by each other (figure 6B). 
Co-immunoprecipitation with overexpressing various recombinant YY1 proteins (figure 6A) revealed 
that the spacer domain of YY1 was critical for the interaction with TonEBP (figure 6C). Next, Yc1, an 
N-terminal truncated TonEBP with intact rel-homology domain (RHD) (figure 6A), interacted with 
YY1 in a spacer-dependent manner (figure 6D) indicating that the C-terminal two thirds of TonEBP 
was dispensable for the interaction. Deletion of RHD domain abolished the interaction with YY1 
(figure 6E) indicating the importance of RHD. Thus, the interaction between TonEBP and YY1 is 
mediated by RHD and spacer domain. 
 In summary, local inflammation stimulates the assembly of an enhanceosome on the COX-2 
promoter (figure 6F, bottom). This assembly is dependent on YY1 binding to its cognate site on DNA. 
Of interest, TonEBP is required for the recruitment of both YY1 and p300 to the promoter in situ. The 
critical role of TonEBP in PGE2 production provides a mechanistic basis for the strong association of 








2-5. TABLES AND SUPPLEMENTARY TABLES 
Table 2-1. Univariate and multivariate analyses of postoperative recurrence, metastasis, and 





Note: tNT0 and tNT1 are defined in figure 2-1J; tT0 and tT1 are defined in figure 2-1K. A 
multivariate analysis was carried out to identify the independent predictor for recurrence and survival 
using the Cox regression hazard model. Rec (+), recurrence; Rec(-), Non-recurrence 
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Table 2-S1. Clinical characteristics of enrolled patients with HCC who received surgical 
resection 
Characteristics Patients (n=296) 
Age (mean ± S.D.) 56.6 ± 9.8 
Sex (male/female) 249/47 
Causes of HCC (HBV/HCV/Alcohol/Others) 234/25/26/11 
Underlying liver disease (CH/LC) 63/233 
Child-Pugh class: A/B/C 280/16/0 
Model for End-Stage Liver Disease score 
 
        < 10 269 
        ≥10 27 
Tumor size (cm, mean ± S.D.) 4.5 ± 3.3 
Tumor number: Single/Multiple 254/42 
Tumor staging, n (%) 
 
   Very early (0) 50 (16.9) 
   Early (A) 216 (73.0) 
   Intermediate (B) 30 (19.1) 
Microvessel invasion, n (%) 89 (30.1) 
Metastasis, n (%) 61 (20.6) 
Postoperative recurrence, n (%) 144 (48.6) 
Death, n (%) 84 (28.4) 

















Table 2-S2. Association of non-tumor TonEBP expression with clinical parameters 
Variables 
tNT0 (t0) tNT1 (t1 to t4) 
P value 
( n = 130) (n = 166) 
Age (mean ± S.D.) 55.7±9.1 57.3±10.4 0.164 
Sex (male/female) 113/17 136/30 0.243 
Tumor size (cm) 3.90 ± 3.45 4.99 ± 3.19 0.005 
E-S grade (I:II:III:IV) 3:67:54:6 6:58:90:12 0.039 
Microvascular invasion 34 55 0.194 
Lymphovascular invasion 16 33 0.082 
Bile duct invasion 3 8 0.257 
Recurrence 48 96 <0.001 
Metastasis 20 41 0.049 
Death 32 52 0.204 
HBV 97 137 0.097 
HCV 14 11 0.203 
AFP (ng/mL) 1266±7357 4620±22295 0.071 
PIVKA-II (mAU/mL) 633±2460 2978±12850 0.029 
Preoperative HBV DNA (log10 IU/mL) 1.78±2.24 2.57±2.44 0.015 
Underlying liver disease (CH/LC) 30/100 33/133 0.505 
Child-Pugh class: A/B/C 121/9/0 159/7/0 0.446 
Model for End-Stage Liver Disease score 5.40±4.65 5.30±3.25 0.830 
 


















Table 2-S3. Association of tumor TonEBP expression with clinical parameters 
Variables 
tT0  (t0 and t1) tT1  (t2 to t4) 
P value 
( n = 80) (n = 216) 
Age (mean ± S.D.) 56.3 ± 9.4 56.8 ±10.0 0.686 
Sex (male/female) 68/12 181/35 0.801 
Tumor size 4.07 ± 3.63 4.68 ± 3.22 0.163 
E-S grade (I:II:III:IV) 4:46:28:2 5:79:116:16 0.003 
Microvascular invasion 16 73 0.022 
Lymphovascular invasion 8 41 0.065 
Bile duct invasion 1 10 0.299 
Recurrence 29 115 0.006 
Metastasis 10 51 0.036 
Death 15 69 0.025 
HBV 57 177 0.045 
HCV 8 17 0.558 
AFP (ng/mL) 1344 ± 7703 3815 ± 19856 0.124 
PIVKA-II (mAU/mL) 358 ± 789 2544 ± 11456 0.008 
Preoperative HBV DNA (log10 IU/mL) 1.74 ± 2.21 2.41 ± 2.43 0.069 
Underlying liver disease (CH/LC) 23/57 40/176 0.080 
Child-Pugh class: A/B/C 73/7/0 207/9/0 0.121 
Model for End-Stage Liver Disease score 5.36±4.52 5.34±3.68 0.962 
 














Table 2-S4. TonEBP haplo-deficiency is resistant to DEN-induced liver injury 
  PBS DEN 
  TonEBP+/+ TonEBP+/Δ TonEBP+/+ TonEBP+/Δ 
Albumin (g/dL) 6.13 ± 0.133 5.47 ± 0.267 * 8.30 ± 0.518 # 6.64± 0.122 * 
ALT (U/L) 29.33± 1.333 28 ± 2.309 158± 37.038 # 57.6 ± 12.875 * 
AST (U/L) 110.67 ± 7.055 137.33 ± 14.111 192.5 ± 21.739 # 151.6 ± 10.074 * 
LDH (U/L) 214 ± 22.983 388.27 ± 70.483 682.25 ± 97.885 # 477.4 ± 41.019 * 
Urea (mg/dL) 101.33 ± 19.230 118.67 ± 1.333 131.5 ± 9.809 # 111.2 ± 5.744 * 
Creatinine (mg/dL) 0.6 ± 0.040 0.61 ± 0.013 0.7 ± 0.030 # 0.6 ± 0.018 * 
Total bile acid (mg/dL) 101.2 ± 12.427 101.87 ± 19.683 9.6 ± 2.877 # 18.12 ± 4.198 * 
Total bilirubin (mg/dL) 0.148 ± 0.028 0.111 ± 0.003 0.1235 ± 0.011 0.1044 ± 0.008 
Direct bilirubin (mg/dL) 0.197 ± 0.047 0.125 ± 0.001 0.137 ± 0.009 # 0.1304 ± 0.007 
 

























Table 2-S5. TonEBP haplo-deficiency is resistant to DEN/HFD-induced liver injury 
  DEN/ND DEN/HFD 
  TonEBP+/+ TonEBP+/Δ TonEBP+/+ TonEBP+/Δ 
Albumin (g/dL) 4.28 ± 0.17 4.13 ± 0.33 * 6.56 ± 0.32 # 5.83 ± 0.26 * 
ALT (U/L) 71.11 ± 14.78 43.75 ± 8.76 * 310.63 ± 42.86 # 243.89 ± 21.24 * 
AST (U/L) 170.00 ± 11.15 136.25 ± 8.3 * 316.25 ± 36.05 # 186.11 ± 15.47 * 
Glucose (mg/dL) 149.44 ± 13.45 110 ± 8.45 124.38 ± 10.78 143.33 ± 6.61 
TG (mg/dL) 44.44 ± 2.94 48.13 ± 2.51 69.38 ± 7.26 # 49.44 ± 3.48 * 
Cholesterol (mg/dL) 110.56 ± 10.49 96.25 ± 7.60 289.38 ± 23.24 # 271.11 ± 30.98 
LDH (U/L) 595.67 ± 36.43 498.06 ± 37.13 * 1251.19 ± 167.21 # 741.94 ± 81.09 * 
 

















Table 2-S6. TonEBP expression was associated with COX-2 expression in patients with HCC 
 
tNT0 tNT1 Total P value 
cNT0 91 85 176 
0.001 cNT1 39 81 120 
Total 130 166 296 
 tT0 tT1 Total P value 
cT0 47 86 133 
0.004 cT1 33 130 163 
Total 130 166 296 
 
tNT0 and tNT1 are defined in Figure 1J and tT0 and tT1 are defined in Figure 1K.  
COX-2 staining intensity was assigned to five grades as TonEBP (c0 – c4). COX-2 expression in Non-
tumor region was stratified to cNT0 (c0, n=176) vs. cNT1 (c1-c4, n=120) and that in tumor region 















2-6 SUPPLEMENTARY FIGURES 
Figure 2-S1. Hepatic TonEBP expression is elevated in HCC. 
 
(A) Intensity of TonEBP bands in Figure 1B was measured and shown in mean + SD, n = 7. *p < 0.05 
compared to non-tumor. (B) TonEBP mRNA was measured from a tumor and its surrounding non-
tumor region in each of 25 patients. (C) Intensity of TonEBP immunohistochemical staining from 
















Figure 2-S2. Hepatic TonEBP expression is associated with poor postoperative prognosis in 
patients with HCC 
 
(A,B) Kaplan-Meier plot of (A) cumulative metastasis and (B) overall survival in patients whose non-
tumor expression of TonEBP was t0 (tNT 0) vs. those patients whose non-tumor expression was 
higher – t1 to t4 (tNT 1). (C,D) Kaplan-Meier plot of (C) cumulative metastasis and (D) cumulative 














Figure 2-S3. Elevated expression of TonEBP in HCC was associated with a fall in the abundance 
of miR-223. 
 
(A) RT-qPCR analysis of miR-223 in HepG2 cells incubated for 12 h in normoxia or hypoxia (2% 
oxygen). Mean + SD, n = 3. *p < 0.05 compared to normoxia. (B) RT-qPCR analysis of miR-223 in 
non-tumor and tumor regions from HCC patients analyzed in figure 1G. Mean + SEM, n = 38, *p < 
0.05 compared to corresponding non-tumor. (C) RT-qPCR analysis of miR-223 in non-tumor and 
tumor regions from DEN-treated animals analyzed in figure 1A. Mean + SEM, n = 18, *p < 0.05 
compared to corresponding non-tumor. (D) RT-qPCR analysis of TonEBP in cells transfected with 
miRNA-223 mimic (miR-223) or non-specific control RNA (NC). n = 3. *p < 0.05 compared to NC. 



















Figure 2-S4. Expression of TonEBP is associated with inflammation in patients with HCC. 
 
TonEBP vs. inflammatory gene transcript abundance in tumors from 100 HCC patients. Data were 

















Figure 2-S5. TonEBP promotes oxidative stress-induced cell death and inflammation 
 
(A) Immunoblot analyses of HepG2 cells transfected with TonEBP-targeting siRNA or non-specific 
scrambled (Scr) siRNA followed by a 24 h treatment with 0 to 2 mM H2O2 as indicated. (B) HepG2 
cells were transfected with siRNA followed by a treatment with H2O2. LDH was measured from 
cultured medium and concentration was expressed relative to treatment with no H2O2. Mean ± SD, n = 
3. *p < 0.05 compared to TonEBP siRNA. (C) Cells transfected with siRNA were treated for 24h with 
hypoxia (2% oxygen) or normoxia. LDH was measured from cultured medium. *p < 0.05 compared 
to corresponding Scr siRNA. #p<0.05 compared to corresponding normoxia. (D) RT-qPCR analyses 
of TonEBP, TNFα, or IL-1β in cells transfected with siRNA followed by treatment with 1 mM H2O2 
for up to 12 h, as indicated. Mean + SD, *p < 0.05 compared to corresponding Scr siRNA. #p<0.05 

















Figure 2-S6. TonEBP-induced paracrine factors promote cell proliferation 
 
(A) HepG2 cells transfected with pcDNA3.1 or TonEBP-pcDNA3.1 were immunoblotted 48 h later. 
(B) Cells were transfected as in A. 24 h later TNFα (10 ng/ml), IL-1β (20 ng/ml), or vehicle (Con) 
were added, and then, the cells were cultured for an additional 24 h followed by trypsinization and 
cell counting. Mean + SD, n = 4. *p < 0.05 compared corresponding pcDNA3.1. #p < 0.05 compared 
corresponding Con. (C) Cells were transfected with siRNA. They were treated with TNFα or IL-1β 
and counted as in B. (D) Cells transfected as in A were seeded on a permeable support. The 
transfected cells were co-cultured above a bed of non-transfected for 24 h. IL-1β was added to the 
medium and the cells cultured for an additional 48 h before counting of the non-transfected cells. (E) 



















Figure 2-S7. Body weight and blood glucose in animals treated with DEN and fed with HFD 
 
(A) Experimental scheme of DEN (diethylnitrosamine) or PBS (phosphate-buffered saline: vehicle) 
injection and feeding with HFD (high fat diet) or ND (normal diet) in TonEBP+/Δ mice and their 
TonEBP+/+ littermates. (B) Body weight during the 30 week with HFD (n = 15) or ND (n = 12). Mean 
± SEM. +/+: TonEBP+/+ mice. +/Δ: TonEBP+/+ mice. p<0.05: a, +/+ vs. +/Δ in PBS + HFD; b,+/+ vs. 
+/Δ in DEN + HFD; c, PBS + HFD vs. DEN + HFD in +/+. (C,D) Serum blood glucose levels after 24 















Figure 2-S8. Signaling and hepatic inflammation in hepatocyte- and myeloid-specific TonEBP 
deficiency 
 
(A) Livers, kidneys, white adipose tissues (WAT), and brains from 10 week old TonEBPfl/fl; Albumin 
cre+/- mice (HKO) and their TonEBPfl/fl; Albumin cre-/- (WT) littermates were analyzed by 
immunoblotting (2 animals from each genotype) or RT-qPCR (n = 7). *p < 0.05 compared to 
corresponding WT. (B) Immunohistochemical images of TonEBP in hepatic tissues from WT or HKO 
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mice. (C) Animals were treated with DEN. 48 h later, livers were immunoblotted for p38, JNK, and 
ERK, and their phosphorylated forms (p-p38, p-JNK, and p-ERK). 3 animals were used from each 
genotype. (D) Immunohistochemical images of TonEBP in hepatic tissues from WT or MKO mice. (E) 
Serum ALT was measured 48 h after injection with PBS (n = 5) or DEN (n = 7) into TonEBPfl/fl; Lys-
M cre+/- mice (MKO) and their TonEBPfl/fl; Lys-M cre-/- (WT) littermates. Mean + SEM, *p < 0.05 
compared to corresponding WT. (F) RT-qPCR analyses of inflammatory genes and proliferation 































Figure 2-S9. TonEBP deficiency attenuates inflammation in hepatocytes 
 
(A–C) RT-qPCR analyses of inflammatory genes in HepG2 cells transfected with siRNA. (A) The 
transfected cells were treated for up to 6 hr as indicated with LPS (500 ng/ml). (B,C) The transfected 
cells were treated for 6 h with (B) IL-1β (20 ng/ml), (C) TNFα (10 ng/ml), or vehicle only (Con). (D) 
AML-12 cells were transfected with siRNA and treated for 6 h with 10 ng/ml of IL-1β or 80 ng/ml of 
TNFα. mRNA was analyzed as above. Mean + SD, n = 4. *p < 0.05 compared to Scr siRNA. #p < 












Figure 2-S10. TonEBP stimulates COX-2 expression and PGE2 production. 
 
(A) RT-qPCR of COX-2 in non-tumor and tumor region from HCC patients analyzed in figure 1G. 
Mean + SEM, n = 38, *p < 0.05 compared to corresponding non-tumor. (B) HepG2 cells transfected 
with siRNA were treated for 6 h with IL-1β or vehicle (Con). COX-2 mRNA was measured by RT-
qPCR. Mean + SD, n = 4. *p < 0.05 compared to corresponding Scr siRNA. #p<0.05 compared to 
corresponding Con. (C) Intensity COX-2 bands in Figure 5C was quantified and shown in mean + SD. 
n = 6. *p < 0.05 compared to TonEBP+/+. (D) Serum PGE2 levels in TonEBP+/Δ or TonEBP+/+ animals 
fed with ND (n = 7) or HFD (n = 8) from Figure 3. Mean + SEM. *p < 0.05 compared to 
corresponding TonEBP+/+. #p < 0.05 compared to corresponding ND. (E, F) Serum PGE2 levels in 
PBS- (n = 5) and DEN-treated animals (n = 6) from (E) figure 4B – D and (F) supplementary figure 
8C,D. (G) HepG2 cells transfected with siRNA were treated with IL-1β as indicated. PGE2 was 
measured from culture medium. n = 4. Mean + SD, *p < 0.05 compared to corresponding Scr. #p < 
0.05 compared to corresponding -. (H) Cells transfected with miR-223 or NC as in Figure 1L were 
subjected to a 24 h hypoxia or normoxia. TonEBP, COX-2, and Hsc70 were visualized by 
immunoblotting. (I) Cells transfected as in supplementary figure 6A followed by transfection of scr 
siRNA or COX-2 siRNA were seeded on a permeable support. The transfected cells were co-cultured 
above a bed of non-transfected for 24 h. IL-1β was added to the medium and the cells cultured for an 






Figure 2-S11. TonEBP-dependent stimulation of COX-2 requires transcription factor YY1. 
 
(A) HepG2 cells were transfected with promotorless vector (pGL3), COX-2 promoter reporter with 
2.5 kb of sequence containing a TonEBP binding site (COX-2 2.5kb) or with 1 kb of sequence without 
TonEBP site (COX-2 1kb). Luciferase activity was measured and expressed relative to pGL3 
transfected cells. Means of 2 independent experiments are shown. (B) HepG2 cells were transfected 
with siRNA followed by a second transfection with pGL3, COX-2 2.5kb (COX-2), or a mutant COX-
2 promoter reporter whose TonEBP binding site was inactivated (ΔTonE). Luciferase activity was 
measured after treatment without or with IL-1β. Mean + SD, n = 3. *p<0.05 compared to 
corresponding Scr. (C) Cells were transfected with various combinations of TonEBP-targeted, YY-1-
targeted, and Scr siRNA (-) as indicated. They were treated with IL-1β and RT-qPCR was performed 
to analyze TonEBP, YY1, and COX-2 mRNA. Mean + SD, n = 4. (D) Cells transfected with siRNA 
were treated for 1 h with IL-1β and immunoblotted. Ton, TonEBP. (E) Cells were transfected and 









Given that HCC is a heterogeneous disease with diversity in etiological agents, tumor architectures, 
histological characteristics, repertoire of oncogenic mutations, and gene expression profiles, it is 
remarkable that elevated TonEBP expression in tumors over non-tumor regions is observed in more 
than 90% of HCC patients. TonEBP is more prevalent than any other immunohistochemical 
biomarker of HCC and the first one associated with inflammation. [37, 38] The widespread elevation 
in tumor TonEBP levels demonstrates that inflammation is the common feature of heterogeneous 
HCC. In the cohort of HCC patients studied here, higher tumor TonEBP expression predicts death, 
and is associated with tumor size, grade, recurrence, and metastasis. COX-2 expression is driven by 
the elevated TonEBP leading to the production of PGE2 which promotes tumorigenesis and 
progression [32-34] providing a mechanistic basis for the TonEBP as a part of the common pathway 
activated by the diverse etiological agents (figure 6F). 
  Hepatic resection has been the treatment of choice for early HCC. However, resection is associated 
with a 70% recurrence rate in the remaining hepatic tissue [39]. Post-operative recurrence is classified 
as early or late depending on whether the recurrence occurs within 2 years of resection or not. 
Remarkably, TonEBP mRNA expression was higher in the non-tumor regions of patients who had 
early recurrence compared to those who did not. In the cohort of HCC patients, higher non-tumor 
TonEBP expression predicts recurrence and metastasis, and is associated with tumor size and grade. 
We observe COX-2 expression is also driven by TonEBP in this region. PGE2 is known to educate 
inflammatory tumor microenvironment to promote tumor progression by orchestrating crosstalk 
between tumor cells and their microenvironment [32-34]. Thus, the TonEBP-COX-2-PGE2 pathway 
contributes to recurrence. Given the complexity of cellular mechanisms involved in recurrence,39 we 
suspect that there might be other pathways of TonEBP such as cell migration10 that contribute to 
recurrence (figure 6F). 
Studies in various mouse models of HCC and hepatitis reveal additional TonEBP actions upstream 
of inflammation. The diverse insults that cause HCC impose oxidative stress [40] leading to cell 
injury and inflammation. Experiments with TonEBP-deficient animals and cultured hepatocytes 
demonstrate that TonEBP promotes the cell injury and inflammation in response to oxidative stress 
(Figure 6F). In addition, TonEBP expression is dramatically elevated in response to oxidative stress 
providing a positive reinforcement. Thus, TonEBP is intrinsically involved in multiple steps in the 
cellular pathways stimulated by the various insults that cause HCC. This explains the strong 
association of hepatic TonEBP and poor prognosis in the HCC patients. On the other hand, since our 
patient cohort is heavily biased to HBV-driven HCC the association needs more robust verification in 
patients with other etiologies. 
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The data presented here suggest that targeting TonEBP is an attractive strategy to prevent 
recurrence as well as hepatocarcinogenesis and metastasis. In this regard, three distinct action sites of 
TonEBP can be considered (figure 6F): 1) cell injury and inflammation, 2) induction of TonEBP by 
oxidative stress and downregulation of miR-223, and 3) transcriptional stimulation of COX-2 and 
other pro-inflammatory genes. We reported that a small compound cerulenin inhibited the 
transcriptional stimulation of pro-inflammatory genes including COX-2 by blocking the interaction of 
TonEBP and p3006. We find that cerulenin blocks the IL-1β-induced transcription of COX-2 in 
hepatocytes (data not shown). Cerulenin and other agents that target any of the three sites of TonEBP 
action might be proved efficacious in preventing recurrence and metastasis for HCC patients whose 
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Chapter 3. TonEBP promotes therapeutic resistance and tumorigenic 
potential of liver cancer stem cells via DNA repair and inflammation 
 
3-1. ABSTRACT 
Hepatocellular carcinoma (HCC) is a cancer with the 2nd most mortality. Inherent resistance to 
chemotherapeutic agents and a high rate of recurrence are the major contributing factors. Cancer stem 
cells (CSCs) are responsible for these pathological properties due to its highly activated DNA repair. 
Despite increasing evidence, a mechanistic understanding of liver CSCs is still lacking. Here, I 
reported that TonEBP promotes therapeutic resistance and recurrence of HCC via DNA repair of liver 
CSCs. In 3 different HCC cell lines, TonEBP was required for self-renewal of liver CSCs analyzed by 
sphere formation. In addition, TonEBP knockdown reduced maintenance of liver CSCs. Due to its role, 
TonEBP promotes tumorigenic activity of liver CSCs in animals. Chemoresistance, the major 
characteristic of CSCs, was mediated by TonEBP in combination with higher repair activity. TonEBP-
mediated DNA repair was responsible for ERCC1/XPF dimer. TonEBP interacted with ERCC1/XPF 
dimer through RHD domain and was required for DNA recruitment of this complex. ERCC1/XPF-
mediated self-renewal of liver CSCs was dependent on TonEBP. The TonEBP-ERCC1/XPF complex 
activated ATM in response to DNA damage leading to activation of transcription factors and 
expression of pro-inflammatory cytokines, which stimulate the self-renewal of CSCs. Of interest, in a 
cohort of 296 patients with HCC, expression of ERCC1-XPF predicted recurrence, metastasis, and 
death with high significance in multivariate analyses in TonEBP dependent manner. Thus, the 
TonEBP-ERCC1/XPF complex is an attractive target for the prevention of recurrence and 










Liver cancer is a common cancer with high mortality: the 2nd most leading cause of cancer-
associated death (< 8 % of 5 year survival rate) and the 6th most common malignancy in worldwide 
[1]. Hepatocellular carcinoma (HCC) is the major histological subtype, accounting for 70% – 85% of 
cases of primary liver cancer [2]. The 5-year recurrence rate of HCC patients remains poor and major 
issue of HCC treatment [3]. Diverse etiological agents in the setting of chronic liver diseases and wide 
heterogeneity in individual tumors impede limited therapeutic options [4]. Inherent resistance to 
chemotherapeutic agents and a very high rate of recurrence are the major contributing factors [5]. 
Complete removal of advanced HCC by operative resection is difficult because of its metastatic 
potential [6].  
Cancer stem cells (CSCs) are responsible for these pathological properties [7, 8] due to its highly 
activated DNA damage responses [9, 10]. CSCs, a small subset within solid tumor, are considered to 
be the source of recurrent and acquired chemoresistant tumors [11]. Recently, several liver CSC 
markers have been identified, including EPCAM, CD133, CD13, and CD90 [12, 13]. Given the 
critical role of CSCs in tumorigenesis, targeting of self-renewal of CSC can be an attractive strategy 
for tumor treatment. However, a mechanistic understanding of liver CSCs is still lacking unlike other 
cancers.  
Tonicity-responsive enhancer binding protein (TonEBP), also known as NFAT5, is a central 
component of the inflammatory enhanceosome in which TonEBP bridges activated transcription 
factors to histone acetyltransferase p300 on gene promoters of inflammatory cytokines [14]. TonEBP 
expression is stimulated by inflammation leading to elevated expression of pro-inflammatory genes in 
chronic inflammatory diseases [15-17]. Previously we demonstrated that TonEBP promotes 
hepatocarcinogenesis, recurrence, and metastasis [18]. The expression of TonEBP in HCC tissues is 
higher compared to adjacent non-tumor tissues in 92.6% of HCC patients regardless of etiology 
associated. Of great interest, expression of TonEBP predicts recurrence, metastasis, and death in 
multivariate analyses. Three common sites of TonEBP action in response to diverse etiological agents 
leading to tumorigenesis and tumor growth were found: cell injury and inflammation, induction by 
oxidative stress, and stimulation of the COX-2 promoter. However, it is still unclear the underlying 
molecular mechanism of recurrence and metastasis contributed by TonEBP. In this study, we 
demonstrated that TonEBP is a central component of signaling mechanism of liver CSCs promoting 
recurrence and chemotherapeutic resistance. TonEBP was required to self-renewal, maintenance, and 
chemotherapy resistance of liver CSCs. Experiments in animals revealed that TonEBP mediates 
tumorigenic potential of liver CSCs. DNA repair of liver CSCs in response to chemotherapeutic 
agents inducing intra- and inter-strand DNA crosslinks requires TonEBP. Function of ERCC1/XPF, a 
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key component of repair in DNA crosslinks, in liver CSCs, chemoresistance, and predicting post-

























3-3. MATERIALS AND METHODS 
Human HCC samples and clinical information 
This research was approved by the Institutional Review Board at the Ulsan University Hospital 
(UUH 2015-12-018). A total of 296 patients who underwent hepatic resection for HCC from January 
2008 to February 2017 at the Ulsan University Hospital, University of Ulsan, College of Medicine, 
Ulsan, Korea, were included in the study. All patients were HCC treatment-naïve before surgery. All 
296 patients who underwent hepatic resection had a grossly complete resection. The patients were 
predominantly males (84.1%) with average age of 56.6 years. The median follow-up period was 37 
months (range = 1-119 months). Postoperative recurrence was observed in 146 cases (49.3%). The 2-, 
5-year HCC recurrence rates were 43.6% and 61.1%, respectively. During postoperative follow-up 
period, metastasis and death were observed in 61 (20.6%) and 86 (29.1%) of cases, respectively. Data 
were expressed as mean +/- standard deviation or median (range). For statistical significance, Student 
t test and chi-squared test were used for comparisons of variables between groups. The cumulative 
relapse and survival rates were evaluated by the Kaplan-Meier method, and differences were 
determined by the log-rank test. A multivariate analysis was carried out to identify the independent 
predictor for recurrence and survival using the Cox regression hazard model. All data were analyzed 
using the statistical package SPSS for Windows (version 21.0; SPSS Inc.). In all cases, a two-tailed P-
value less than 0.05 was considered statistically significant. Additional protocols and procedures are 
described in methods.  
 
Cell line 
HCC cell line, Hep3B from American Type Culture Collection (ATCC) was maintained in modified 
Eagle's medium (MEM, Hyclone) supplemented with 10% fetal bovine serum (FBS; Thermo) with 
penicillin-streptomycin (Hyclone). PLC/PRF/5 and Huh7 cells were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 supplemented with 2.05 mM L-glutamine, 25mM Hepes, 10% fetal 
bovine serum, and penicillin-streptomycin. Cells were transfected with TonEBP siRNA or control 
scrambled siRNA using lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s 
instructions. Control shRNA and TonEBP shRNA was used for generating lentivirus-mediated stable 
knockdown HCC cell lines. Cells were transfected with lentiviral constructs expressing TonEBP 
shRNA or control shRNA as described above for 24 hr. Positive cells were selected with puromycin 




Sphere formation assay 
Cells were seeded on ultra-low attachment culture dishes (Corning) in serum-free medium. 
DMEM/F12 serum-free medium (Invitrogen) contained 2 mM L-glutamine, 1% sodium pyruvate 
(Invitrogen), 100 μg/ml penicillin G, and 100 U/ml streptomycin supplemented with 20 ng/ml 
epithelial growth factor (Invitrogen), 10 ng/ml fibroblast growth factor-2 (Invitrogen), N2 (Invitrogen), 
and B27 (Invitrogen). Cells were incubated in a CO2 incubator for one to two weeks. 
 
Flow cytometry and cell sorting 
Cells were stained using antibodies according to the manufacturer’s instructions. Labeled cells were 
detected using a FACSCalibur (BD Immunocytometry Systems). For cell sorting, cocktail PE-
conjugated anti-human CD133 and FITC-conjugated anti-human CD90 antibodies were incubated 
with cells. Then cells were sorted with FACS Aria III (BD Immunocytometry Systems). 
 
Xenograft transplantation of CSCs 
All the methods involving live mice were carried out in accordance with the approved guidelines. All 
experimental protocols were approved by the Institutional Animal Care and Use Committee of the 
Ulsan National Institute of Science and Technology (UNISTACUC-12-15-A). 
For subcutaneous injection models, different dilutions of control and treated cells were implanted 
into mice (female BALB/c nude mice), aged 4 to 6 weeks, with Matrigel Basement Membrane Matrix 
(BD biosciences) into two sides of the same nude mouse at the posterior dorsal flank region (n = 8). 
Tumors were measured every other day. The mice were maintained under standard conditions 
according to the institutional guidelines for animal care. 
 
Immunohistochemistry (IHC) and histology analysis 
Liver tissues were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 5 μm 
sections. Paraffin sections were deparaffinized and dehydrated. Antigen of was retrieved by citrate 
and peroxidase or EDTA and peroxidase in appropriate time for each antigen. Anti-ERCC1 antibodies, 
anti-XPF antibodies, anti-CD133 antibodies, anti-CD90 antibodies, anti-ALDH1 antibodies, and anti-





Human HCC patient tissue samples were collected as previously described. H&E of each patient was 
analyzed by histologist and representative paired hepatic tumor and adjacent non-tumor region of 296 
HCC patients in formalin-fixed paraffin-embedded tissue was marked and extracted for tissue array. 
Then, extracted tissue was arranged, molded by using tissue microarray cassette, and solidified for 
tissue array analysis. The arrays were processed simultaneously for ERCC1 and XPF 
immunohistochemistry and signal intensity was assigned to 3 (t0 to t2) using an image software 
(Image J). 
 
Immunofluorescence, microscopy, and image analysis 
Cells were plated in LabTek chamber slides (Thermo Fisher Scientific) and incubated for 1 day 
before fixation with 100% methanol at 20°C for 30 min. For chromatin-bound proteins, cells were 
pretreated with 0.5% Triton X-100 for 2 min before fixation. Edu (Thermo Fisher Scientific) labeling 
is performed as manufacturer’s instructions (Click-iT™ EdU Alexa Fluor™ 594 Imaging Kit).  
 
Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated using the TRIzol reagent (Invitrogen) followed by chloroform and ethanol 
precipitation. cDNA was synthesized by M-MLV reverse transcriptase (Promega) according to the 
manufacturer’s instructions. After reverse transcription, Q-PCR was performed using SYBR Green I 
Master and LightCycler 480 II (Roche). Measured cycle threshold values were normalized with 
GAPDH and they were expressed as fold-over control samples. All qRT-PCR reactions were 
duplicated. Adequacy of GAPDH as a house keeping gene was confirmed by NormFinder. 
 
Immunoblotting 
Cell lysis for protein extraction was performed as previously described. Protein concentration was 
measured by BCA system (Pierce). Equal amounts of protein from each sample were separated by 
SDS-PAGE and immunoblotted using specific primary antibodies. HRP-conjugated secondary 
antibodies were used for detection. The antigen-antibody binding was detected by enhanced 




Nuclear, Cytoplasmic, and tight chromatin-bound fractionation 
Cells were harvested by using scrapper and centrifuged. The cell pellet was washed by suspension 
with PBS. The cell nucleus and cytoplasm were separated by using Nuclear and Cytoplasmic 
extraction kit (Pierce) according to manufacturer’s instruction. Tight chromatin-bound fraction was 
isolated as previously described [19]. In brief, cell pellets were sequentially washed in CEBN buffer 
(10 mM HEPES [pH 7.8], 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 0.2 % NP-40, 
1X protease inhibitor cocktail (Invitrogen), and 1X phosphatase Inhibitor cocktail), CEB buffer 
(CEBN buffer without NP-40), soluble nuclear buffer (3 mM EDTA, 0.2 mM EGTA, protease and 
phosphatase inhibitor as described above), and salt buffers with 0.45 M NaCl buffer.  
 
Quantification and statistical analysis 


















TonEBP promotes self-renewal of liver cancer stem cells 
 
Figure 3-1. TonEBP is required for the self-Renewal of liver cancer stem cells. (A) Immunoblots 
of TonEBP and Hsc70 was performed in lysates of tumorsphere cells (S) and non-tumorsphere cells 
(NS) (B) TonEBP mRNA levels in liver CSCs (CD90+CD133+) compared to non-stem cancer cells 
(CD90-CD133-) sorted from 3 HCC cell lines, PLC/PRF/5 (PLC), Huh7, and Hep3B (n = 4). Mean + 
SD, *p < 0.05. (C) TonEBP expression was stably reduced by lentiviral knockdown of TonEBP 
(shTon) or control vector (shCon) in PLC/PRF/5 cells. Representative images from sphere formation 
assay (left). Percentages of sphere-forming cells were analyzed as mean + SD, (n = 3), *p < 0.05.  
(D) ALDH activity was analyzed in isolated liver CSCs. Mean + SD, (n = 6), *p < 0.05. (E) 
PLC/PRF/5 cells transfected with pcDNA3.1 or pcDNA3.1-TonEBP were immunoblotted 48 later. 
(F) Transfected cells from (E) were cultured for sphere formation assay. Representative images from 
sphere formation assay (left) and percentages of sphere-forming cells were analyzed as mean + SD, 
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(n = 3), *p < 0.05. (right). (G) Liver CSCs (CD90+CD133+) in PLC/PRF/5 cells were analyzed by 
FACS. (H) Tumorigenic potential (left) and tumorigenic frequency (right) was analyzed by limiting 
dilution assay. (I,J) RT-qPCR analyses of EMT genes and stem cell transcription factor (TF) in 
PLC/PRF/5 cells with (I) stably knockdown of TonEBP expression or (J) overexpression TonEBP 
followed by sphere cell formation assay. Mean + SD, (n = 4), *p < 0.05. 
 
We previously demonstrated that expression of TonEBP in HCC is markedly increased compared to 
non-tumor regions surrounding tumors and predicts post-operative poor outcome in patients with 
HCC [18]. Since CSCs are the subset within tumor, we investigated TonEBP expression in population 
of CSCs to examine the association of TonEBP-mediated poor prognosis and CSCs. To investigate the 
role of TonEBP in poor prognosis, the function of TonEBP in liver cancer stem cells was examined. 
Since CSCs are the subset within tumor, I firstly investigated TonEBP expression in population of 
CSCs to examine the association of TonEBP-mediated poor prognosis and CSCs. Functional isolation 
by sphere cell (figure 3-1A) and biochemical isolation by widely recognized surface marker CD133 
and CD90 by FACSaria analysis (figure 3-1B) revealed that TonEBP expression was notably 
increased in liver CSCs in different cell lines of liver cancer. These data potentiated that TonEBP may 
be involved in the self-renewal of liver CSCs. 
To demonstrate the function of TonEBP in self-renewal of liver CSCs, we next performed sphere 
formation assay. Lentiviral knockdown of TonEBP significantly reduced sphere formation (figure 3-
1C) and ALDH activity (figure 3-1D) while its overexpression (figure 3-1E) enhanced sphere 
formation (figure 3-1F). Maintenance of liver CSCs (figure 3-1G) was also suppressed in cells treated 
with TonEBP shRNA.  
Given the association of TonEBP and liver CSCs, we analyzed function of TonEBP in tumorigenic 
potential. We performed sphere formation and digested tumorspheres of TonEBP-deficient or WT 
cells into single-cell suspension, then subcutaneously injected 104, 103, 102 and 101 cells into BALB/c 
nude mice. Tumor initiating capacity was examined third month after injection. TonEBP deficiency 
remarkably suppressed tumor-initiating capacity (figure 3-1H). In mirroring to this observation, 
sphere cells whose TonEBP was reduced by shRNA or overexpressed revealed decrease or increase of 
stem cell transcription factors and epithelial–mesenchymal transition genes respectively (figure 3-1I,J) 
suggesting that TonEBP might play a role in the liver CSCs. These data confirmed that TonEBP 
promotes the self-renewal of liver CSCs. 
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Figure 3-2. TonEBP-mediated DNA damage response is greater in cancer stem cells. (A) 3 HCC 
cell lines were transfected with TonEBP siRNA or scrambled (Scr) siRNA, followed by treatment of 
cisplatin (5μM) or vehicle (DMF) for 48 h before counting the viable cells. Mean + SD, (n = 4), *p < 
0.05. (B) Liver CSCs (CD133+) and non-stem cancer cells (CD133-) were isolated in PLC/PRF/5 
cells by MACS system, followed by siRNA transfection. Viable cells were counted after incubation 
with cisplatin for 48 h. mean + SD, (n = 4), *p < 0.05. (C) 3 HCC cell lines were transfected with 
TonEBP siRNA or scrambled (Scr) siRNA, followed by treatment of UV (5μM) as indicated 
intensity for 24 h before counting the viable cells. Mean + SD, (n = 4), *p < 0.05. (D) PLC/PRF/5 
cells were transfected with TonEBP siRNA or scrambled (Scr) siRNA, followed by treatment of 
MMC (5μM) or vehicle (Veh) for 48 h before counting the viable cells. Mean + SD, (n = 4), *p, #p < 
0.05. (E) Isolated cells as (B) were incubated with MMC or Veh for 48 h before counting the viable 
cells. (F) Nuclear extracts were prepared from PLC/PRF/5 cells transfected with siRNA followed by 
treatment with cisplatin for 6 h. Phosphorylation of Chk1 and Chk2 were analyzed by 
immunoblotting. (G) Representative images from cells labeled with Edu stain. (H,I) Liver CSCs 





TonEBP-mediated chemoresistance is greater in CSCs 
Increasing evidence suggests that CSCs contributes to chemotherapy resistance of cancer by both 
very efficient in repairing DNA damage and expressing high levels of efflux transporters [7, 12]. A 
CSC phenotype is a known character of chemoresistant tumors. Since the data discussed above show 
that TonEBP promotes self-renewal of liver CSCs, we next investigated the role of TonEBP in 
chemoresistance using cisplatin which induce cell death via intra- and inter-strand DNA crosslink. 
TonEBP deficiency sensitized cisplatin in three different HCC cell lines (figure 3-2A). CD133 
positive PLC/PRF/5 cells enriched by MACS system were less sensitive to cisplatin compared to 
CD133 negative cells, supporting an association of cancer cells with stem-like feature with drug 
resistance. Of note, TonEBP-mediated cisplatin resistance was greater in CD133 positive HCC cells 
(figure 3-2B), suggesting that chemoresistance in cancer stem cells stems from in part TonEBP. 
To understand TonEBP-mediated cisplatin resistance, ultraviolet (UV) and mitomycin C (MMC)-
responsive cell death were examined to analyze intra- and inter-strand crosslinks respectively. Both 
damaging agents displayed similar results to cisplatin (figure 3-2C, D) demonstrating that TonEBP is 
involved in both pathways. 
As TonEBP is a regulator of chemoresistance in association with DNA repair pathway, we examined 
TonEBP-mediated pathway. Cisplatin-responsive phosphorylation of checkpoint Kinase 1 (Chk1) and 
checkpoint Kinase 2 (Chk2) was reduced in TonEBP deficient CD133 positive HCC cells (figure 3-2E) 
demonstrating repair of DNA crosslink in liver CSCs requires TonEBP. In line with this, proliferation 
of DNA labeled by Edu was reduced in TonEBP deficient CD133 positive HCC cells (figure 3-2G). 
As expected, H2AX phosphorylation (Figure 3-2G) and foci formation (figure 3-2H) were reduced in 
TonEBP deficient CD133 positive HCC cells. These results demonstrate that TonEBP mediates DNA 
repair of liver CSCs and TonEBP deficiency increases DNA damage accumulation in liver CSCs. 
 
TonEBP interacts with ERCC1/XPF via RHD domain 
 We asked the molecular mechanism underlying the regulation of DNA repair. TonEBP-interacting 
proteins were identified using liquid chromatography-tandem mass spectrometry. One of the proteins 
picked by the procedure was ERCC1/XPF. Expression of ERCC1/XPF is associated with 
chemoresistance and poor post-operative prognosis in a variety of cancer types [20-22]. However, 
little is known about role of ERCC1/XPF in liver cancer and cancer stem cells. We confirmed that 
ERCC1 and XPF were co-immunoprecipitated by TonEBP; plus the interactions were stimulated by 
UV or cisplatin treatment without changing their expression (figure 3-3A). Since their interaction was 
observed on the chromatin (figure 3-3b), we analyzed chromatin fraction in response to cisplatin 
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treatment. Cisplatin-responsive chromatin binding of ERCC1/XPF was reduced in TonEBP deficient 
cells without changes in their upstream signaling proteins; XPA and XPD (figure 3-3C). In addition, 
TonEBP deficiency displayed no changes in expression of repair genes (figure 3-3D) demonstrating 
that TonEBP-mediated DNA repair activity was dependent on protein interactions. 
Figure 3-3. TonEBP interacts with ERCC1/XPF. (A) Lysates of PLC/PRF/5 cells treated with UV 
(upper) or MMC (bottom) were immunoprecipitated (IP) as indicated. Lysates and 
immunoprecipitates were immunoblotted for TonEBP, ERCC1, and XPF. (B) Tight chromatin bound 
fraction from PLC/PRF/5 cells treated with UV (upper) or MMC (bottom) were immunoprecipitated 
(ChIP) as indicated. Lysate and immunoprecipitates were immunoblotted TonEBP, ERCC1, and 
XPF. (C) Tight chromatin bound fractions were prepared from PLC/PRF/5 cells transfected with 
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siRNA followed by treatment with cisplatin (4h). Immunoblots of ERCC1, XPF, XPA, XPD, and 
histone 3 (H3) were performed. (D) RT-qPCR analyses of DNA repair genes in PLC/PRF/5 cells 
transfected with siRNA. (E) Lysates of HEK293T cells transfected with pcDNA3.1-ERCC1, -XPF, 
and –TonEBP were immunoprecipitated with normal serum (serum), anti-TonEBP antibodies, 
normal IgG (IgG), anti-XPF antibodies, or anti-ERCC1 antibodies. Lysates (left) and 
immunoprecipitates (right) were immunoblotted for TonEBP, ERCC1, and XPF. (F-H) Lysates of 
HEK293 cells transfected with or without the indicated vectors were immunoprecipitated with anti-
Myc or Flag antibodies, followed by immunoblotting. (I,J) PLC/PRF/5 cells were transfected with 
TonEBP siRNA and a plasmid expressing full-length (I) TonEBP and TonEBP ΔRHD (ΔRHD) or (J) 
Yc1, or Yc1 ΔRHD. Cells were cultured for sphere formation assay. Percentages of sphere-forming 
cells were analyzed as mean + SD (n = 3). 
 
To characterize the interaction between TonEBP and ERCC1/XPF, we performed co-
immunoprecipitation experiments. Overexpressed TonEBP and ERCC1 or XPF were mutually pulled 
down by each other (figure 3-3E). Previous studies demonstrated that TonEBP binds to its cognate 
DNA sequence using the rel-homology domain (RHD) similar to the RHD containing transcription 
factors NFAT and NFκB [14, 23]. The RHD of TonEBP forms a homodimer that completely encircles 
DNA creating a protein ring [24]. In addition, previous observation demonstrated that RHD is 
responsible for protein-protein interaction of TonEBP. We therefore examined the effect of RHD to 
the interaction. Deletion of RHD abolished the interaction with ERCC1/XPF (figure 3-3F,G). N-
terminus of TonEBP (Yc1), which encompasses the entire RHD, interacted with ERCC1/XPF and the 
interaction required RHD indicating the importance of RHD (figure 3-3H). The role of the RHD was 
further confirmed by performing reconstitution experiments. After knockdown of endogenous 
TonEBP, cells were transfected with siRNA-resistant full-length TonEBP or RHD-deleted TonEBP 
(ΔRHD). Sphere formation was restored by full-length TonEBP, but not by ΔRHD (figure 3-3I). In 
addition, Yc1 is sufficient to stimulate sphere formation and RHD is required for restoration (figure 3-
3J). These results demonstrated that RHD region of TonEBP interacting with DNA repair protein, 
ERCC1/XPF dimer, was critical in self-renewal of liver CSCs. 
We next explored the function of ERCC1/XPF to self-renewal of liver cancer stem cells. Knockdown 
of ERCC1 or XPF reduced the self-renewal of CSCs just as in the knockdown of TonEBP (figure 3-
4A). Knockdown of XPF reduced population of liver CSCs in HCC cells in FACS analysis (figure 3-
4B). TonEBP-stimulated sphere formation is mediated by ERCC1/XPF indicating importance of 
TonEBP-ERCC1/XPF axis in liver CSCs (figure 3-4C). As expected, DNA damage was accumulated 
in XPF deficient liver CSCs (figure 3-4D). 
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Figure 3-4. ERCC1/XPF is required for the self-Renewal of liver cancer stem cells. Expression 
of ERCC1 and XPF was stably reduced by lentiviral knockdown (shERCC1 or shXPF) or control 
vector (shCon) in PLC/PRF/5 cells. (A) Representative images from sphere formation assay. (B) 
Liver CSCs (CD90+CD133+) in PLC/PRF/5 cells were analyzed by FACS. (C) PLC/PRF/5 cells 
stably expressing low ERCC1/XPF or not were transfected with pcDNA3.1 or control vector, 
followed by sphere formation assay. Representative images from sphere formation assay (left) and 
percentages of sphere-forming cells were analyzed as mean + SD (n=3), *p < 0.05. (right). (D) Liver 
CSCs were isolated as figure 3-2. Immunoblots of p-γH2AX 
 
TonEBP-ERCC1/XPF promotes DNA damage-induced ATM/inflammation activation 
The results discussed above demonstrated that TonEBP-ERCC1/XPF is required to DNA repair and 
self-renewal of liver CSCs. To understand the link between DNA repair and cancer stemness, we 
analyzed ataxia-telangiectasia mutated (ATM) serine/threonine kinase, a key protein in DNA repair, 
that initiate activation of the DNA damage checkpoint, leading to cell cycle arrest, DNA repair, or 
apoptosis[25-27]. Of note, highly activated ATM revealed disadvantage in survival of cancer patients 
[28]. We observed that knockdown of TonEBP or XPF remarkably reduced phosphorylation of ATM 
in response to UV or MMC (figure 3-5A,B). Activation of ATM is considered to exert its function in 
self-renewal of CSCs by activation of downstream transcription factors including NF-κB or STAT3 
[29,30]. Notably, increasing evidence revealed that these transcription factors activate inflammatory 
cytokines and genes implicated in stemness including EMT, metastatic potential, and chemoresistance 
[31-34]. TonEBP or XPF knockdown also impeded UV- or MMC-responsive phosphorylation of both 
transcription factors (figure 3-5A,B). Target genes of transcription factors displayed UV or MMC 
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responsiveness while TonEBP or XPF knockdown reversed them (figure 3-5C,D) suggesting pivotal 
role of TonEBP-ERCC1/XPF in DNA damage-induced inflammatory activation.  
Figure 3-5. TonEBP-mediated DNA damage-induced inflammation is mediated by ATM. (A,B) 
Immunoblotting of lysates with the indicated antibodies from PLC/PRF/5 cells transfected with 
siRNA followed by (A) treatment of UV and incubation in culture medium for 2h or by (B) 
incubation with MMC for 4h (C,D) RT-qPCR analyses of inflammatory genes (TNFα, IL-8, IL-1β, 
CCL2) in PLC/PRF/5 cells transfected with siRNA followed by (C) treatment of UV and incubation 
in culture medium for 6h or by (D) incubation with MMC for 6h. Mean + SD, (n = 4), *p < 0.05.  
(E) Isolated liver CSCs from shRNA transfected cells were incubated with or without ATMi or BAY 
for 48 h. ALDH activity was analyzed.  Mean + SD, (n = 3), *p < 0.05. (F) Immunoblotting of 
lysates with indicated antibodies from PLC/PRF/5 cells transfected with siRNA followed by 
incubation with hydroxyurea (HU, 5mM) for 4h. (G,H) PLC/PRF/5 cells were transfected with 
siRNA followed by incubation with DMSO or ATMi. Cells were washed with PBS and treated with 
UV followed by incubation in culture medium for (G) 2 h for immunoblotting with the indicated 




To understand the role of ATM kinase and NF-κB in TonEBP-mediated stemness of liver CSC, 
inhibitor of NF-κB (BAY) or ATM kinase (KU55933, ATMi) were treated. As expected, inhibition of 
ATM kinase or NF-κB significantly reduced stemness of liver CSCs, but no changes were displayed 
between control and TonEBP deficient cells in inhibitor-treated group (figure 3-5E). These data 
suggest that ATM kinase and NF-κB are the downstream effector of TonEBP-mediated stemness 
regulation. However, there was no change in TonEBP-mediated ATM kinase activation in response to 
hydroxyurea (figure 3-5F), another DNA damaging agent, confirming the role of TonEBP in repair of 
DNA crosslink-responsive ATM kinase activation. 
To examine pivotal role of ATM kinase in TonEBP-ERCC1/XPF-mediated activation of transcription 
factors NF-κB or STAT3, ATMi was treated. ATMi treatment reduced ATM activation as previously 
studied. Activation of NF-κB or STAT3 displayed no change in ATMi treated cells while it was 
dramatically reduced in DMSO treated cells (figure 3-5G). In line with activation of transcription 
factors, target genes revealed parallel results (figure 3-5H). These results implicated the crucial role of 
ATM kinase in TonEBP function. 
 
ERCC1 and XPF predict poor prognosis of HCC in TonEBP dependent manner 
To further explore the clinical implications of ERCC1/XPF in HCC, we examined hepatic tissues 
obtained from 296 HCC patients (table 3-S1). The expression of ERCC1/XPF was negative in most of 
non-tumor regions surrounding HCCs indicating the function of ERCC1/XPF in DNA repair. We 
stratified the patients into 3 groups according to immunohistochemical analyses (negative, weak 
positive, strong positive). Expression of ERCC1/XPF in tumor was significantly correlated as shown 
in cell lines that single knockdown of them induced decreased expression of both proteins (figure 3-
6A). Univariate analysis of three layers of patients showed that negative or strong positive tumor 
ERCC1/XPF expression was significantly associated with recurrence, metastasis (i.e., extrahepatic 
metastasis), and death (table 3-S2,3). Kaplan-Meier Kaplan-Meier plot confirmed the higher 
recurrence, metastasis, and death in patients with negative or strong positive tumor ERCC1/XPF 
expression (figure 3-6B-D). As described above, expression of ERCC1/XPF is associated with poor 
prognosis or chemoresistance. We concluded that accumulated DNA damages in ERCC1/XPF 
negative patients drive poor prognosis as previously described, while increased DNA repair activity 
and stimulated self-renewal of liver CSCs might be a driving potential in ERCC1/XPF strong positive 
patients. These results pointed toward a correlation of ERCC1/XPF expression and the post-operative 
poor outcome of patients with HCC. 
We further investigated ERCC1/XPF’s role in post-operative prognosis by multivariate analyses 
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(table 3-1). As for recurrence, tumor size, microvascular and lymphovascular invasion along with 
tumor ERCC1/XPF expression displayed strong association (table 1). Male sex, ALT levels, albumin 
levels, tumor size, tumor grade, microvascular invasion, and tumor ERCC1/XPF expression showed 
robust association with metastasis. Finally, microvascular invasion, albumin levels, and tumor 
ERCC1/XPF were significantly associated with overall survival. We conclude that hepatic 
ERCC1/XPF expression predicts post-operative recurrence, metastasis, and death in HCC patients. 
We next examined TonEBP dependency in ERCC1/XPF-mediated post-operative poor outcome in 
patients with HCC. The activity of ERCC1-XPF in predicting post-operative poor outcome was 
dependent on high expression of TonEBP in univariate analysis (Table 5) and Kaplan-Meier analysis 
(figure 3-6E) confirming the role of TonEBP-ERCC1/XPF in recurrence and metastasis as shown in 
sphere formation. In addition, expression of TonEBP was significantly correlated with expression of 
XPF or ERCC1 in patients with poor prognosis (figure 3-6F). Thus, we conclude that ERCC1/XPF 
mediate the TonEBP’s actions on post-operative poor outcome in HCC. 
 
Figure 3-6. ERCC1/XPF-associated poor prognosis is dependent on TonEBP. (A) Representative 
images of ERCC1 and XPF immunohistochemical staining of tumor from tissue arrays processed 
simultaneously. Staining intensity was assigned to three grades as shown (0-2). (B-D) Kaplan-Meier 
plot of postoperative (B) recurrence, (C) metastasis, and (D) survival in three layers of patients as 
described in table 3-S2 and S3. (E) Kaplan-Meier plot of postoperative recurrence, metastasis, and 
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survival in two layers of patients of low or high expression of TonEBP in tumor with strong positive 
expression of ERCC1 and XPF. (F) Correlation of TonEBP expression with expression of XPF and 
ERCC1 in tumor areas of hepatic tissues from patients with HCC poor prognosis including 

























Table 3-1. Univariate and multivariate analyses of postoperative recurrence, metastasis, and 




Note: eT0-2 and xT0-2 are defined in figure 3-6A. A multivariate analysis was carried out to identify 
the independent predictor for recurrence and survival using the Cox regression hazard model. Rec (+), 
recurrence; Rec(-), Non-recurrence 




Age (mean ± S.D.) 56.6 ± 9.8 
Gender (male/female) 249/47 
Causes of HCC (HBV/HCV/Alcohol/Others) 234/25/26/11 
Underlying liver disease (CH/LC) 63/233 
Child-Pugh class: A/B/C 280/16/0 
Model for End-Stage Liver Disease score   
        < 10 269 
≥10 27 
Tumor size (cm, mean ± S.D.) 4.5 ± 3.3 
Tumor number: Single/Multiple 254/42 
Tumor staging, n (%)   
   Very early (0) 50 (16.9) 
   Early (A) 216 (73.0) 
   Intermediate (B) 30 (19.1) 
Microvessel invasion, n (%) 89 (30.1) 
Metastasis, n (%) 68(23.0) 
Postoperative recurrence, n (%) 146 (49.3) 
Death, n (%) 100 (33.8) 











Table 3-S2. Association of tumor XPF expression with clinical parameters 
Variables 
xT0 
( n = 109) 
xT1 
(n = 91) 
xT2 
(n = 96) 
P value 
Tumor size (cm) 4.891±3.9489 3.829±2.4267 4.733±3.2841 0.060 
E-S grade (I:II:III:IV) 1:37:62:9 3:46:38:4 5:42:44:5 0.109 
Microvascular invasion 39 16 34 0.008 
Lymphovascular invasion 28 10 11 0.005 
Bile duct invasion 1 4 6 0.121 
Recurrence 71 19 56 0.000 
Metastasis 35 5 28 0.000 
Death 44 16 40 0.000 
HBsAg 85 74 75  
antiHCV 11 7 7 0.736 
AFP (ng/mL) 3116.10±13439.18 1809.53±9586.15 4449.86±25487.21 0.587 
PIVKA-II (mAU/mL) 3414.96±15216.534 1171.46±5153.209 1095.43±3714.160 0.188 
Preoperative HBV DNA 
(log10 IU/mL) 
2.5930±2.54818 1.5999±2.08901 2.5090±2.38802 0.024 
Underlying liver disease 
(CH/LC) 
18/91 21/70 24/72 0.294 
Child-Pugh class: A/B 102/7 84/7 94/2 0.200 
Model for End-Stage Liver 
Disease score     
5.48±3.841 5.05±3.468 5.47±4.398 0.699 
Age (mean ± S.D.) 55.61±9.622 56.47±10.339 57.94±9.578 0.238 
AST 49.64±30.813 38.46±19.806 43.29±25.010 0.010 
ALT 45.40±31.452 38.01±24.313 39.44±25.548 0.127 
Gender (male/female) 94/15 80/11 75/21 0.140 
 









Table 3-S3. Association of tumor ERCC1 expression with clinical parameters 
Variables 
eT0 
( n = 95) 
eT1 
(n = 100) 
eT2 
(n = 101) 
P value 
Tumor size (cm) 4.782±4.0251 4.017±2.4499 4.751±3.3872 0.190 
E-S grade (I:II:III:IV) 0:35:53:7 3:50:43:4 6:40:48:7 0.098 
Microvascular invasion 31 23 35 0.159 
Lymphovascular invasion 23 10 16 0.028 
Bile duct invasion 0 5 6 0.063 
Recurrence 56 26 64 0.000 
Metastasis 26 7 35 0.000 
Death 30 22 48 0.001 
HBsAg 78 79 77 0.601 
antiHCV 8 7 10 0.761 
AFP (ng/mL) 1656.26±11448.400 1974.20±9430.193 5710.32±26014.950 0.190 
PIVKA-II (mAU/mL) 2710.57±12615.918 1126.31±4938.151 2125.75±9832.837 0.558 
Preoperative HBV DNA 
(log10 IU/mL) 
2.9309±2.58280 1.52000±1.91336 2.3667±2.44938 0.001 
Underlying liver disease 
(CH/LC) 
13/82 22/78 28/73 0.055 
Child-Pugh class: A/B 88/7 93/7 99/2 0.171 
Model for End-Stage Liver 
Disease score     
5.60±3.871 5.25±3.488 5.20±4.361 0.741 
Age (mean ± S.D.) 56.17±10.202 55.77±10.399 57.92±8.868 0.259 
AST 46.83±28.245 40.93±20.220 44.80±29.384 0.280 
ALT 42.00±22.118 38.99±25.337 42.62±33.897 0.612 
Gender (male/female) 81/14 88/12 80/21 0.218 
 













( n = 42) 
tT1 
(n = 122) 
P value 
Tumor size (cm) 3.302±2.2397 4.645±3.0654 0.007 
E-S grade (I:II:III:IV) 0:13:19:10 1:16:46:59 0.024 
Microvascular invasion 6 40 0.021 
Lymphovascular invasion 1 15 0.062 
Bile duct invasion 1 9 0.243 
Recurrence 10 64 0.001 
Metastasis 3 26 0.038 
Death 7 43 0.024 
HBsAg 33 97 0.897 
antiHCV 4 8 0.524 
AFP (ng/mL) 139.017±560.9188 4739.211±23948.8731 0.023 
PIVKA-II (mAU/mL) 2710.57±12615.918 1126.31±4938.151 0.016 
Preoperative HBV DNA (log10 
IU/mL) 
1.0973±1.70193 2.2099±2.32879 0.072 
Underlying liver disease 
(CH/LC) 
14/28 29/93 0.224 
Child-Pugh class: A/B 39/3 118/4 0.285 
Model for End-Stage Liver 
Disease score     
4.131±0.5340 4.177±0.4967 0.872 
Age (mean ± S.D.) 56.86±7.176 56.66±10.448 0.146 
ALT 36.64±26.943 39.79±24.798 0.533 
Gender (male/female) 35/7 100/22 0.841 
 










Hepatic resection has been the treatment of choice for early HCC. However, resection is associated 
with a 70% recurrence rate and second-most lethal cancer in HCC, implicating that post-operative 
treatment is required [3]. Recently, CSCs have been focused in many solid tumors as a therapeutic 
target of cancer prognosis including recurrence, metastasis, and chemoresistance [7, 8]. Despite 
increasing evidence, understanding link between DNA repair and poor prognosis remain poor in 
cancer stem cells. Our previous study revealed potential of TonEBP as a new target of HCC treatment 
in which it promotes hepatic inflammation, injury, and HCC development [18]. Here, our study 
suggests an uncovered molecular mechanistic basis underlying barrier in HCC treatment; recurrence 
and chemoresistance. We again proposed that TonEBP is an attractive therapeutic target since TonEBP 
promotes chemoresistance and recurrence by DNA repair and self-renewal of liver CSCs. 
ERCC1/XPF dimer has been recognized DNA repair protein in a variety of DNA damage response. 
Although the dimer is widely studied chemoresistance and poor prognosis in several cancers [20-22], 
its potential as therapeutic target is undervalued In patients with HCC, we stratified the patients 
according to their ERCC1/XPF expression into 3 layer; negative, weak positive, or strong positive. 
Previous studies stratifying the patients with ERCC1/XPF expression into 2 groups as positive and 
negative did not come to a same conclusion, while higher expression of ERCC1/XPF displayed poor 
prognosis compared to lower expressing group. This may explain why the role of ERCC1/XPF in 
cancer prognosis has been neglected while function of the dimer is recognized in chemoresistance in 
the past. Here, we clearly demonstrated that ERCC1/XPF strong positive patients showed 
disadvantages while weak positive patients showed improved post-operative prognosis. In vitro and 
clinical findings also suggested that TonEBP mediates the function of ERCC1/XPF. 
Inflammatory activation caused by DNA damage has been considered as ‘driving cue’ for chronic 
diseases and cancer stemness [35-37]. We and others have demonstrated that TonEBP is a critical 
regulator of chronic inflammatory diseases in which it activates the promoter of proinflammatory 
genes as transcription co-activator. Here, we proposed a novel pathway of TonEBP in onset of 
inflammation that TonEBP activates ATM kinase signaling by interaction with ERCC1/XPF dimer 
followed by activation of NF-κB and STAT3. TonEBP mediates DNA damage responsive 
ERCC1/XPF recruitment on the chromatin and is required to DNA repair. Thus, given the importance 
of inflammatory cytokines and transcription factors, TonEBP-ERCC1/XPF-ATM axis promotes self-
renewal of liver CSCs and chemoresistance. Although we demonstrated that TonEBP promotes 
development, recurrence, and chemoresistance of HCC, the role of TonEBP associated with cancer in 
the timeline is still unclear. In addition, binding protein decision of TonEBP in a variety of different 
responses, transcription regulation of TonEBP expression, and phenotypic regulation of TonEBP 
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overexpressing animals should be uncovered. 
RHD of TonEBP was suggested responsible element for the protein interaction in previous studies. 
RHD of TonEBP is a critical region for the activation of transcription enhanceosome on the COX-2 
promoter through interaction with histone acetyltransferase p300 and transcription factor YY1. PGE2 
production from enhanced COX-2 expression promotes hepatic inflammation and HCC initiation and 
growth. Again, RHD interacts with ERCC1/XPF dimer and is required to TonEBP-mediated self-
renewal of liver CSCs. Thus, it is suspected that targeting RHD to inhibit the protein interaction might 
be an attractive target not only for the prevention of recurrence and effective chemotherapy in HCC 
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Cancer has been the target of intense investigation because it is a leading cause of mortality 
worldwide with increased incidence. Cancer is a critical issue affecting all aspect of human life of all 
societies. Unfortunately, cancer occurs by a variety of underlying diseases and its complexity is driven 
by diverse ‘driving cue’ of a series of mutation in genes followed by promotion and progression. 
Recent studies demonstrated that genetic alterations from carcinogens including viral infection, 
smoking, or obesity promote tumorigenesis by giving rise to chronic inflammation. And interplay of 
immune cells and mutated cells plays decisive role at every single stage of tumor development; 
initiation, promotion, malignancy, recurrence, and metastasis. Thus, chronic inflammation increases 
cancer risk and protumorigenic mediator. 
Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. 
HCC is the sixth most common cancer and the second most common cause of cancer-related death 
worldwide with steadily increasing incidence. The characteristic high mortality of HCC is due to a 
combination of multiple factors: difficulty in early detection, lack of effective treatments and 
extremely high rates of recurrence and metastasis. The major etiological agents are HBV, HCV and 
alcoholic or non-alcoholic fatty liver. HCC occurs within a setting of chronic inflammation driven by 
a variety of etiological agents. Therefore, investigating the microenvironment might uncover a 
common molecular pathway useful for a prognostic biomarker and therapeutic target. 
Stem-like cancer cells or cancer stem cells (CSCs), a small subset residing in solid tumor, are 
considered to be the source of recurrence, metastasis, and inherent chemoresistance of tumor. 
Inflammatory microenvironment provides niches for the CSCs. However, mechanistic understanding 
of liver CSCs is still lacking unlike other cancers. 
In this study, I discovered uncovered novel pathway of liver disease: TonEBP promotes development, 
recurrence, and chemotherapy resistance of HCC via inflammation and cancer stem cells. 
1. TonEBP expression is higher in tumors than in adjacent non-tumor tissues in 92.6% of HCC 
patients regardless of etiology associated. The TonEBP expression in tumors and adjacent non-tumor 
tissues predicts recurrence, metastasis, and death in multivariate analyses. TonEBP drives the 
expression of cyclooxygenease-2 (COX-2) by stimulating the promoter in association with 
transcription factor YY1 and p300. RHD of TonEBP mediates TonEBP-dependent COX-2 activation. 
In mouse models of HCC, three common sites of TonEBP action in response to diverse etiological 
agents leading to tumorigenesis and tumor growth were found: cell injury and inflammation, 
induction by oxidative stress, and stimulation of the COX-2 promoter. TonEBP is a key component of 
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the common pathway in tumorigenesis and tumor progression of HCC in response to diverse 
etiological insults.  
2. TonEBP was required for self-renewal of liver CSCs analyzed by sphere formation. In addition, 
TonEBP knockdown reduced maintenance of liver CSCs. TonEBP promotes tumorigenic activity of 
liver CSCs in animals. Chemoresistance, the major characteristic of CSCs, was mediated by TonEBP 
in combination with higher repair activity. TonEBP-mediated DNA repair was responsible for 
ERCC1/XPF dimer. TonEBP interacted with ERCC1/XPF dimer through RHD domain and was 
required for DNA recruitment of this complex. ERCC1/XPF-mediated self-renewal of liver CSCs was 
dependent on TonEBP. The TonEBP-ERCC1/XPF complex activated ATM in response to DNA 
damage leading to activation of transcription factors and expression of pro-inflammatory cytokines, 
which stimulate the self-renewal of CSCs. Of interest, in a cohort of 296 patients with HCC, 
expression of ERCC1-XPF predicted recurrence, metastasis, and death with high significance in 
multivariate analyses in TonEBP dependent manner. 
We have suggested that RHD of TonEBP is responsible for the protein interaction in several studies. 
RHD of TonEBP is a critical region for the activation of transcription enhanceosome on the COX-2 
promoter. Again, RHD interacts with ERCC1/XPF dimer and is required to TonEBP-mediated self-
renewal of liver CSCs. Thus, we suspected that targeting RHD to inhibit the protein interaction might 
be an attractive target not only for the prevention of recurrence and effective chemotherapy in HCC 
but also for pathogenesis of chronic inflammatory diseases including cancer. However it is still 
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